| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.92 | 0 | 0.92 | Cell wall synthesis inhibitor | 0.174 0.044 DBMET03516 0.119 0.101 DBMET00960 | ||
| 0.914 | 0.001 | 0.914 | Antibacterial | |||
| 0.461 | 0.016 | 0.461 | DNA synthesis inhibitor | 0.337 0.033 DBMET03516 0.274 0.053 DBMET00960 | ||
| 0.228 | 0.016 | 0.228 | Antibacterial (Helicobacter pylori) | 0.13 0.067 DBMET03516 | ||
| 0.32 | 0.127 | 0.32 | Beta lactamase inhibitor | |||
| 0.209 | 0.038 | 0.355 | Acetylcholine M1 receptor antagonist | 0.355 0.008 DBMET03516 0.308 0.013 DBMET00960 | DBMET03516 | |
| 0.118 | 0.036 | 0.194 | Acetylcholine M3 receptor agonist | 0.194 0.005 DBMET03516 | DBMET03516 | |
| 0.163 | 0.082 | 0.163 | Phospholipase C inhibitor | 0.161 0.086 DBMET03516 | ||
| 0.087 | 0.013 | 0.091 | Elastase inhibitor | 0.091 0.012 DBMET00960 | DBMET00960 | |
| 0.197 | 0.135 | 0.197 | Streptokinase A inhibitor | |||
| 0.125 | 0.102 | 0.802 | Cholinergic | 0.463 0.007 DBMET03516 0.802 0.004 DBMET00960 | DBMET00960 | |
| 0.031 | 0.02 | 0.031 | Elastase 2B inhibitor | |||
| 0.031 | 0.02 | 0.031 | Elastase 3A inhibitor | |||
| 0.031 | 0.02 | 0.031 | Elastase 3B inhibitor | |||
| 0.006 | 0.001 | 0.006 | Antibiotic Penicillin-like | |||
| 0.036 | 0.073 | 0.1 | Acetylcholine M2 receptor agonist | 0.1 0.007 DBMET03516 | DBMET03516 | |
| 0.009 | 0.132 | 0.032 | Carnitine palmitoyltransferase 1A inhibitor | 0.032 0.015 DBMET03516 | DBMET03516 | |
| 0.027 | 0.182 | 0.051 | CC chemokine receptor 2B antagonist | 0.051 0.029 DBMET03516 | DBMET03516 | |
| 0.049 | 0.211 | 0.271 | Acetylcholine muscarinic antagonist | 0.271 0.012 DBMET03516 0.251 0.014 DBMET00960 | DBMET03516 | |
| 0.043 | 0.213 | 0.106 | Prolactin release inhibitor | 0.106 0.004 DBMET03516 0.066 0.031 DBMET00960 | DBMET03516 | |
| 0.028 | 0.21 | 0.077 | Potassium channel (Ca-activated) blocker | 0.077 0.02 DBMET03516 | DBMET03516 | |
| 0.048 | 0.247 | 0.647 | Acetylcholinesterase inhibitor | 0.225 0.026 DBMET03516 0.647 0.004 DBMET00960 | DBMET00960 | |
| 0.022 | 0.278 | 0.053 | Cyclin H inhibitor | 0.053 0.049 DBMET03516 | DBMET03516 | |
| 0.035 | 0.329 | 0.304 | Acetylcholine antagonist | 0.304 0.013 DBMET03516 0.272 0.017 DBMET00960 | DBMET03516 | |
| 0.019 | 0.323 | 0.291 | Acetylcholine agonist | 0.291 0.006 DBMET03516 0.257 0.008 DBMET00960 | DBMET03516 | |
| 0.034 | 0.34 | 0.375 | Cholinergic antagonist | 0.31 0.013 DBMET03516 0.375 0.009 DBMET00960 | DBMET00960 | |
| 0.01 | 0.321 | 0.145 | Nicotinic receptor alpha4 subunit antagonist | 0.145 0.005 DBMET03516 | DBMET03516 | |
| 0.005 | 0.346 | 0.278 | Substance P antagonist | 0.06 0.012 DBMET03516 0.278 0.004 DBMET00960 | DBMET00960 | |
| 0.007 | 0.349 | 0.074 | Nicotinic receptor beta4 subunit antagonist | 0.074 0.009 DBMET03516 | DBMET03516 | |
| 0.007 | 0.359 | 0.299 | Acetylcholine muscarinic agonist | 0.299 0.004 DBMET03516 0.276 0.004 DBMET00960 | DBMET03516 | |
| 0.011 | 0.377 | 0.044 | Baculoviral IAP repeat-containing protein inhibitor | 0.044 0.039 DBMET03516 | DBMET03516 | |
| 0.004 | 0.372 | 0.269 | Acetylcholine M1 receptor agonist | 0.269 0.004 DBMET03516 0.248 0.004 DBMET00960 | DBMET03516 | |
| 0.014 | 0.392 | 0.231 | Analgesic, opioid | 0.19 0.01 DBMET03516 0.231 0.008 DBMET00960 | DBMET00960 | |
| 0.006 | 0.397 | 0.163 | Acetylcholine M3 receptor antagonist | 0.163 0.01 DBMET03516 0.125 0.014 DBMET00960 | DBMET03516 | |
| 0.005 | 0.399 | 0.162 | Opioid kappa receptor agonist | 0.094 0.01 DBMET03516 0.162 0.005 DBMET00960 | DBMET00960 | |
| 0.005 | 0.413 | 0.038 | Leukocyte elastase inhibitor | 0.038 0.036 DBMET03516 | DBMET03516 | |
| 0.005 | 0.433 | 0.191 | Acetylcholine M2 receptor antagonist | 0.191 0.007 DBMET03516 0.14 0.013 DBMET00960 | DBMET03516 | |
| 0.064 | 0.524 | 0.29 | RNA-directed DNA polymerase inhibitor | 0.29 0.034 DBMET03516 0.202 0.096 DBMET00960 | DBMET03516 | |
| 0.003 | 0.498 | 0.048 | Carnitine palmitoyltransferase inhibitor | 0.048 0.009 DBMET03516 | DBMET03516 | |
| 0.007 | 0.503 | 0.068 | CXC chemokine receptor antagonist | 0.068 0.051 DBMET03516 | DBMET03516 | |
| 0.004 | 0.509 | 0.155 | Neurokinin 1 antagonist | 0.059 0.015 DBMET03516 0.155 0.005 DBMET00960 | DBMET00960 | |
| 0.003 | 0.543 | 0.031 | Vasopressin 1B antagonist | 0.031 0.017 DBMET03516 | DBMET03516 | |
| 0.021 | 0.584 | 0.32 | DNA methyltransferase I inhibitor | 0.32 0.02 DBMET03516 | DBMET03516 | |
| 0.008 | 0.587 | 0.119 | Expectorant | 0.119 0.052 DBMET03516 | DBMET03516 | |
| 0.002 | 0.592 | 0.096 | 5 Hydroxytryptamine 3B antagonist | 0.096 0.005 DBMET03516 | DBMET03516 | |
| 0.003 | 0.609 | 0.039 | Vasopressin 1A antagonist | 0.039 0.015 DBMET03516 | DBMET03516 | |
| 0.004 | 0.621 | 0.124 | Neurokinin antagonist | 0.061 0.024 DBMET03516 0.124 0.007 DBMET00960 | DBMET00960 | |
| 0.007 | 0.626 | 0.441 | Butyrylcholinesterase inhibitor | 0.176 0.026 DBMET03516 0.441 0.005 DBMET00960 | DBMET00960 | |
| 0.004 | 0.625 | 0.046 | Opioid mu receptor agonist | 0.046 0.033 DBMET03516 | DBMET03516 | |
| 0.005 | 0.634 | 0.104 | Opioid mu receptor antagonist | 0.104 0.03 DBMET03516 | DBMET03516 | |
| 0.003 | 0.635 | 0.047 | Carnitine palmitoyltransferase 1 inhibitor | 0.047 0.009 DBMET03516 | DBMET03516 | |
| 0.003 | 0.636 | 0.051 | Vasopressin 1 antagonist | 0.051 0.014 DBMET03516 | DBMET03516 | |
| 0.004 | 0.639 | 0.06 | Dopamine D2 agonist | 0.06 0.021 DBMET03516 | DBMET03516 | |
| 0.004 | 0.659 | 0.069 | Opioid agonist | 0.064 0.026 DBMET03516 0.069 0.024 DBMET00960 | DBMET00960 | |
| 0.004 | 0.66 | 0.162 | 5 Hydroxytryptamine 3 antagonist | 0.162 0.008 DBMET03516 0.082 0.024 DBMET00960 | DBMET03516 | |
| 0.003 | 0.663 | 0.022 | CXC chemokine 5 receptor antagonist | 0.022 0.007 DBMET03516 | DBMET03516 | |
| 0.017 | 0.682 | 0.319 | DNA methylase inhibitor | 0.319 0.023 DBMET03516 | DBMET03516 | |
| 0.008 | 0.678 | 0.122 | Mucolytic | 0.122 0.052 DBMET03516 | DBMET03516 | |
| 0.003 | 0.678 | 0.035 | Nociceptin (N/OFQ) receptor antagonist | 0.035 0.025 DBMET03516 | DBMET03516 | |
| 0.009 | 0.687 | 0.082 | Ca(v)2.2 blocker | 0.082 0.063 DBMET03516 | DBMET03516 | |
| 0.009 | 0.688 | 0.09 | Acid-sensing ion channel blocker | 0.09 0.004 DBMET03516 | DBMET03516 | |
| 0.029 | 0.732 | 0.308 | Insulysin inhibitor | 0.308 0.054 DBMET03516 0.223 0.126 DBMET00960 | DBMET03516 | |
| 0.009 | 0.713 | 0.085 | Potassium channel small-conductance Ca-activated blocker | 0.085 0.009 DBMET03516 | DBMET03516 | |
| 0.057 | 0.763 | 0.24 | Interleukin 2 agonist | 0.24 0.13 DBMET03516 | DBMET03516 | |
| 0.004 | 0.711 | 0.082 | Antidiuretic hormone antagonist | 0.082 0.015 DBMET03516 | DBMET03516 | |
| 0.009 | 0.717 | 0.152 | Histamine H2 receptor antagonist | 0.152 0.009 DBMET03516 | DBMET03516 | |
| 0.005 | 0.714 | 0.092 | CXC chemokine 4 receptor antagonist | 0.092 0.027 DBMET03516 | DBMET03516 | |
| 0.004 | 0.713 | 0.195 | Acetylcholine nicotinic agonist | 0.195 0.008 DBMET03516 0.08 0.057 DBMET00960 | DBMET03516 | |
| 0.009 | 0.719 | 0.037 | Neurokinin 2 agonist | 0.037 0.035 DBMET03516 | DBMET03516 | |
| 0.009 | 0.725 | 0.137 | Opioid antagonist | 0.137 0.03 DBMET03516 | DBMET03516 | |
| 0.008 | 0.729 | 0.212 | 5 Hydroxytryptamine 3 agonist | 0.212 0.004 DBMET03516 0.075 0.031 DBMET00960 | DBMET03516 | |
| 0.021 | 0.742 | 0.542 | Toll-Like receptor 7 agonist | 0.542 0.025 DBMET00960 | DBMET00960 | |
| 0.014 | 0.736 | 0.059 | Immunoglobulin Fc receptor antagonist | 0.059 0.026 DBMET03516 | DBMET03516 | |
| 0.072 | 0.797 | 0.317 | Calcium channel L-type activator | 0.317 0.143 DBMET03516 | DBMET03516 | |
| 0.004 | 0.729 | 0.18 | Macrophage colony-stimulating factor 1 receptor antagonist | 0.085 0.037 DBMET03516 0.18 0.01 DBMET00960 | DBMET00960 | |
| 0.001 | 0.728 | 0.123 | Acetylcholine M4 receptor agonist | 0.123 0.003 DBMET03516 | DBMET03516 | |
| 0.004 | 0.732 | 0.162 | Alkylator | 0.162 0.041 DBMET03516 0.118 0.07 DBMET00960 | DBMET03516 | |
| 0.005 | 0.735 | 0.142 | EphA2 antagonist | 0.142 0.035 DBMET03516 | DBMET03516 | |
| 0.011 | 0.742 | 0.191 | Opioid kappa receptor antagonist | 0.191 0.011 DBMET03516 | DBMET03516 | |
| 0.019 | 0.751 | 0.53 | Toll-Like receptor agonist | 0.53 0.026 DBMET00960 | DBMET00960 | |
| 0.003 | 0.738 | 0.03 | HCV NS5A inhibitor | 0.03 0.015 DBMET03516 | DBMET03516 | |
| 0.003 | 0.74 | 0.064 | Histamine H2 receptor agonist | 0.064 0.013 DBMET03516 0.044 0.028 DBMET00960 | DBMET03516 | |
| 0.004 | 0.741 | 0.2 | Acetylcholine M5 receptor antagonist | 0.2 0.005 DBMET03516 0.172 0.006 DBMET00960 | DBMET03516 | |
| 0.003 | 0.74 | 0.034 | Calcitonin gene-related peptide antagonist | 0.034 0.014 DBMET03516 | DBMET03516 | |
| 0.056 | 0.794 | 0.324 | Ca(v)3.3 blocker | 0.324 0.026 DBMET03516 | DBMET03516 | |
| 0.004 | 0.749 | 0.069 | Opioid delta receptor antagonist | 0.069 0.041 DBMET03516 | DBMET03516 | |
| 0.015 | 0.762 | 0.174 | Antineoplastic alkaloid | 0.174 0.021 DBMET03516 | DBMET03516 | |
| 0 | 0.748 | 0.021 | Carbonic anhydrase X inhibitor | 0.021 0.008 DBMET03516 0.016 0.012 DBMET00960 | DBMET03516 | |
| 0 | 0.748 | 0.021 | Carbonic anhydrase VIII inhibitor | 0.021 0.008 DBMET03516 0.016 0.012 DBMET00960 | DBMET03516 | |
| 0.005 | 0.753 | 0.027 | Baculoviral IAP repeat-containing protein 4 inhibitor | 0.027 0.019 DBMET03516 | DBMET03516 | |
| 0.005 | 0.765 | 0.154 | TRKB antagonist | 0.154 0.045 DBMET03516 | DBMET03516 | |
| 0.004 | 0.777 | 0.244 | Acetylcholine M4 receptor antagonist | 0.244 0.005 DBMET03516 0.231 0.005 DBMET00960 | DBMET03516 | |
| 0.006 | 0.784 | 0.392 | GABA C receptor agonist | 0.392 0.005 DBMET03516 0.307 0.009 DBMET00960 | DBMET03516 | |
| 0.004 | 0.782 | 0.137 | Dopamine agonist | 0.137 0.017 DBMET03516 | DBMET03516 | |
| 0.009 | 0.794 | 0.272 | Telomerase inhibitor | 0.126 0.025 DBMET03516 0.272 0.008 DBMET00960 | DBMET00960 | |
| 0.007 | 0.794 | 0.05 | Phosphodiesterase 7A inhibitor | 0.05 0.04 DBMET03516 | DBMET03516 | |
| 0.004 | 0.793 | 0.085 | Dopamine beta hydroxylase inhibitor | 0.085 0.005 DBMET03516 0.047 0.037 DBMET00960 | DBMET03516 | |
| 0.019 | 0.808 | 0.353 | Gastrin inhibitor | 0.353 0.01 DBMET03516 0.232 0.102 DBMET00960 | DBMET03516 | |
| 0.009 | 0.799 | 0.128 | DOPA decarboxylase inhibitor | 0.128 0.037 DBMET03516 0.118 0.047 DBMET00960 | DBMET03516 | |
| 0.003 | 0.796 | 0.107 | Dopamine D4 agonist | 0.107 0.013 DBMET03516 | DBMET03516 | |
| 0.004 | 0.797 | 0.293 | Cytidine deaminase inhibitor | 0.293 0.02 DBMET03516 | DBMET03516 | |
| 0.005 | 0.801 | 0.164 | Calcium channel N-type blocker | 0.164 0.03 DBMET03516 | DBMET03516 | |
| 0.003 | 0.801 | 0.044 | Membrane dipeptidase inhibitor | 0.044 0.021 DBMET03516 | DBMET03516 | |
| 0.002 | 0.801 | 0.173 | Acetylcholine M5 receptor agonist | 0.173 0.004 DBMET03516 0.088 0.028 DBMET00960 | DBMET03516 | |
| 0.005 | 0.804 | 0.175 | Toll-Like receptor 7 antagonist | 0.175 0.005 DBMET03516 | DBMET03516 | |
| 0.004 | 0.805 | 0.048 | Vasopressin 2 antagonist | 0.048 0.014 DBMET03516 | DBMET03516 | |
| 0.005 | 0.807 | 0.071 | Calcium channel L-type blocker | 0.071 0.051 DBMET03516 | DBMET03516 | |
| 0.001 | 0.809 | 0.06 | Potassium channel small-conductance Ca-activated activator | 0.06 0.008 DBMET03516 | DBMET03516 | |
| 0.004 | 0.816 | 0.076 | CDK4/cyclin D1 inhibitor | 0.076 0.027 DBMET03516 | DBMET03516 | |
| 0.004 | 0.817 | 0.156 | Tyrosine-protein kinase receptor FLT3 inhibitor | 0.156 0.051 DBMET03516 0.104 0.077 DBMET00960 | DBMET03516 | |
| 0.006 | 0.819 | 0.12 | Calcium channel (voltage-sensitive) blocker | 0.12 0.056 DBMET03516 | DBMET03516 | |
| 0.006 | 0.819 | 0.133 | Anticoagulant | 0.133 0.097 DBMET03516 | DBMET03516 | |
| 0.003 | 0.818 | 0.264 | Acetylcholine nicotinic antagonist | 0.264 0.008 DBMET03516 0.163 0.017 DBMET00960 | DBMET03516 | |
| 0.002 | 0.821 | 0.03 | Carboxypeptidase B inhibitor | 0.03 0.029 DBMET03516 | DBMET03516 | |
| 0.003 | 0.822 | 0.069 | Dipeptidyl peptidase IV inhibitor | 0.069 0.01 DBMET03516 | DBMET03516 | |
| 0.004 | 0.824 | 0.146 | Poly(ADP-ribose) polymerase inhibitor | 0.043 0.034 DBMET03516 0.146 0.005 DBMET00960 | DBMET00960 | |
| 0.004 | 0.826 | 0.089 | GABA aminotransferase inhibitor | 0.089 0.036 DBMET03516 | DBMET03516 | |
| 0.003 | 0.825 | 0.625 | Dopamine D5 antagonist | 0.357 0.004 DBMET03516 0.625 0.003 DBMET00960 | DBMET00960 | |
| 0.005 | 0.828 | 0.554 | Potassium channel (Voltage-sensitive) blocker | 0.554 0.01 DBMET03516 0.26 0.063 DBMET00960 | DBMET03516 | |
| 0.005 | 0.835 | 0.458 | Potassium channel blocker | 0.458 0.015 DBMET03516 0.143 0.142 DBMET00960 | DBMET03516 | |
| 0.025 | 0.856 | 0.204 | Glutamate release inhibitor | 0.204 0.005 DBMET03516 0.098 0.046 DBMET00960 | DBMET03516 | |
| 0.002 | 0.833 | 0.043 | CC chemokine 3 receptor antagonist | 0.043 0.028 DBMET03516 | DBMET03516 | |
| 0.008 | 0.839 | 0.175 | Vasodilator | 0.175 0.127 DBMET03516 | DBMET03516 | |
| 0.003 | 0.835 | 0.479 | 5 Hydroxytryptamine 1F agonist | 0.479 0.002 DBMET03516 | DBMET03516 | |
| 0.006 | 0.84 | 0.125 | MAP3K7 inhibitor | 0.125 0.013 DBMET03516 | DBMET03516 | |
| 0.003 | 0.838 | 0.096 | Sphingosine kinase 2 inhibitor | 0.096 0.009 DBMET03516 | DBMET03516 | |
| 0.004 | 0.841 | 0.096 | Protein kinase C epsilon inhibitor | 0.096 0.014 DBMET03516 | DBMET03516 | |
| 0.003 | 0.844 | 0.033 | Opioid delta receptor agonist | 0.033 0.029 DBMET03516 | DBMET03516 | |
| 0.023 | 0.864 | 0.566 | Sigma receptor agonist | 0.566 0.005 DBMET03516 0.152 0.084 DBMET00960 | DBMET03516 | |
| 0.011 | 0.853 | 0.123 | MAP kinase 7 inhibitor | 0.123 0.004 DBMET03516 | DBMET03516 | |
| 0.012 | 0.855 | 0.091 | ErbB-3 antagonist | 0.091 0.048 DBMET03516 | DBMET03516 | |
| 0.004 | 0.847 | 0.062 | CDK4/cyclin D inhibitor | 0.062 0.035 DBMET03516 | DBMET03516 | |
| 0.004 | 0.851 | 0.625 | HERG channel blocker | 0.625 0.007 DBMET03516 0.386 0.03 DBMET00960 | DBMET03516 | |
| 0.007 | 0.855 | 0.063 | GHS receptor agonist | 0.063 0.012 DBMET03516 | DBMET03516 | |
| 0.007 | 0.855 | 0.114 | Glycine receptor agonist | 0.114 0.014 DBMET03516 0.074 0.048 DBMET00960 | DBMET03516 | |
| 0.006 | 0.854 | 0.436 | Alpha-N-acetylglucosaminidase inhibitor | 0.436 0.007 DBMET03516 0.324 0.014 DBMET00960 | DBMET03516 | |
| 0.03 | 0.88 | 0.141 | Lipocortins synthesis antagonist | 0.141 0.119 DBMET03516 | DBMET03516 | |
| 0.001 | 0.852 | 0.032 | 5 Hydroxytryptamine 4 agonist | 0.032 0.005 DBMET03516 0.028 0.009 DBMET00960 | DBMET03516 | |
| 0.003 | 0.855 | 0.183 | Sodium channel blocker | 0.127 0.077 DBMET03516 0.183 0.039 DBMET00960 | DBMET00960 | |
| 0.005 | 0.863 | 0.89 | Bronchodilator | 0.89 0.003 DBMET00960 | DBMET00960 | |
| 0.003 | 0.863 | 0.053 | 5 Hydroxytryptamine 1A agonist | 0.053 0.027 DBMET03516 | DBMET03516 | |
| 0.002 | 0.864 | 0.031 | Glutamate (mGluR3) agonist | 0.031 0.027 DBMET03516 | DBMET03516 | |
| 0.002 | 0.865 | 0.176 | Nicotinic receptor alpha7 subunit antagonist | 0.176 0.005 DBMET03516 0.049 0.045 DBMET00960 | DBMET03516 | |
| 0.005 | 0.869 | 0.204 | Immunostimulant | 0.204 0.118 DBMET03516 0.188 0.128 DBMET00960 | DBMET03516 | |
| 0.003 | 0.867 | 0.059 | Cyclin D3 inhibitor | 0.059 0.017 DBMET03516 | DBMET03516 | |
| 0.002 | 0.866 | 0.108 | Nicotinic alpha7 receptor agonist | 0.108 0.008 DBMET03516 | DBMET03516 | |
| 0.005 | 0.869 | 0.042 | GHS receptor antagonist | 0.042 0.011 DBMET03516 | DBMET03516 | |
| 0.002 | 0.866 | 0.103 | Benzodiazepine agonist | 0.103 0.024 DBMET03516 | DBMET03516 | |
| 0.004 | 0.87 | 0.047 | Protein kinase C beta I inhibitor | 0.047 0.005 DBMET03516 | DBMET03516 | |
| 0.007 | 0.873 | 0.041 | Somatostatin 4 agonist | 0.041 0.021 DBMET03516 | DBMET03516 | |
| 0.002 | 0.872 | 0.028 | Urotensin II antagonist | 0.028 0.011 DBMET03516 | DBMET03516 | |
| 0.004 | 0.874 | 0.047 | 11-Beta-hydroxysteroid dehydrogenase 1 inhibitor | 0.047 0.033 DBMET03516 | DBMET03516 | |
| 0.003 | 0.873 | 0.079 | Fibroblast growth factor 4 antagonist | 0.079 0.019 DBMET03516 | DBMET03516 | |
| 0.003 | 0.876 | 0.089 | Dipeptidyl peptidase inhibitor | 0.089 0.011 DBMET03516 | DBMET03516 | |
| 0.002 | 0.875 | 0.065 | Oxytocin agonist | 0.065 0.013 DBMET03516 0.044 0.028 DBMET00960 | DBMET03516 | |
| 0.001 | 0.874 | 0.02 | Neuraminidase (Influenza B) inhibitor | 0.02 0.017 DBMET03516 | DBMET03516 | |
| 0.047 | 0.922 | 0.299 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.299 0.025 DBMET03516 | DBMET03516 | |
| 0.003 | 0.88 | 0.042 | Glutamate (mGluR8) agonist | 0.042 0.019 DBMET03516 0.041 0.021 DBMET00960 | DBMET03516 | |
| 0.003 | 0.881 | 0.217 | Histamine antagonist | 0.217 0.017 DBMET03516 0.196 0.02 DBMET00960 | DBMET03516 | |
| 0.003 | 0.881 | 0.06 | Histamine H3 receptor agonist | 0.06 0.009 DBMET03516 | DBMET03516 | |
| 0.004 | 0.883 | 0.195 | Histamine N-methyltransferase inhibitor | 0.195 0.006 DBMET03516 0.125 0.027 DBMET00960 | DBMET03516 | |
| 0.004 | 0.885 | 0.145 | Calcium channel blocker | 0.145 0.063 DBMET03516 | DBMET03516 | |
| 0.003 | 0.885 | 0.036 | Potassium channel (Inward rectifier) 1 blocker | 0.036 0.009 DBMET03516 | DBMET03516 | |
| 0.003 | 0.887 | 0.167 | Poly(ADP-ribose) polymerase 1 inhibitor | 0.036 0.029 DBMET03516 0.167 0.005 DBMET00960 | DBMET00960 | |
| 0.003 | 0.886 | 0.236 | Calpain 2 inhibitor | 0.236 0.16 DBMET03516 | DBMET03516 | |
| 0.002 | 0.885 | 0.051 | Sphingosine kinase 1 inhibitor | 0.051 0.015 DBMET03516 | DBMET03516 | |
| 0.014 | 0.898 | 0.386 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.386 0.025 DBMET03516 | DBMET03516 | |
| 0.004 | 0.887 | 0.041 | Vanilloid 3 antagonist | 0.041 0.019 DBMET03516 | DBMET03516 | |
| 0.004 | 0.888 | 0.212 | GABA C receptor rho-1 antagonist | 0.212 0.006 DBMET03516 0.152 0.021 DBMET00960 | DBMET03516 | |
| 0.002 | 0.887 | 0.072 | Nav1.7 sodium channel blocker | 0.064 0.052 DBMET03516 0.072 0.041 DBMET00960 | DBMET00960 | |
| 0.003 | 0.889 | 0.224 | Antihistaminic | 0.224 0.017 DBMET03516 0.202 0.02 DBMET00960 | DBMET03516 | |
| 0.003 | 0.889 | 0.183 | Prostaglandin dehydrogenase inhibitor | 0.183 0.17 DBMET03516 | DBMET03516 | |
| 0.003 | 0.889 | 0.056 | Kainate receptor agonist | 0.056 0.009 DBMET03516 0.048 0.016 DBMET00960 | DBMET03516 | |
| 0.002 | 0.888 | 0.057 | HCV NS3/NS4A protease inhibitor | 0.057 0.023 DBMET03516 | DBMET03516 | |
| 0.03 | 0.917 | 0.33 | MAP kinase kinase 6 inhibitor | 0.33 0.109 DBMET03516 | DBMET03516 | |
| 0.001 | 0.889 | 0.124 | Nicotinic neuronal receptor agonist | 0.124 0.008 DBMET03516 | DBMET03516 | |
| 0.004 | 0.891 | 0.128 | AXL receptor tyrosine kinase inhibitor | 0.128 0.024 DBMET03516 | DBMET03516 | |
| 0.001 | 0.889 | 0.085 | GABA uptake inhibitor | 0.085 0.005 DBMET03516 0.046 0.019 DBMET00960 | DBMET03516 | |
| 0 | 0.889 | 0.061 | Nicotinic alpha4 receptor agonist | 0.061 0.003 DBMET03516 0.016 0.012 DBMET00960 | DBMET03516 | |
| 0.001 | 0.891 | 0.055 | Endothelial nitric-oxide synthase inhibitor | 0.055 0.008 DBMET03516 | DBMET03516 | |
| 0.006 | 0.896 | 0.162 | Ca2+/calmodulin-dependent kinase II beta inhibitor | 0.162 0.113 DBMET03516 | DBMET03516 | |
| 0.003 | 0.894 | 0.263 | Anesthetic local | 0.263 0.017 DBMET03516 | DBMET03516 | |
| 0 | 0.892 | 0.012 | Human herpes virus 5 capsid protein P40 inhibitor | 0.012 0.011 DBMET03516 | DBMET03516 | |
| 0.002 | 0.894 | 0.148 | Nicotinic receptor alpha3 subunit antagonist | 0.148 0.007 DBMET03516 0.039 0.038 DBMET00960 | DBMET03516 | |
| 0.004 | 0.896 | 0.13 | Microtubule formation inhibitor | 0.13 0.051 DBMET03516 | DBMET03516 | |
| 0.001 | 0.894 | 0.054 | Histamine H4 receptor agonist | 0.054 0.004 DBMET03516 | DBMET03516 | |
| 0.002 | 0.896 | 0.024 | Kainate receptor 4 antagonist | 0.024 0.018 DBMET03516 | DBMET03516 | |
| 0.001 | 0.895 | 0.059 | NMDA receptor glycine site agonist | 0.059 0.046 DBMET03516 | DBMET03516 | |
| 0.003 | 0.898 | 0.048 | Bromodomain-containing protein 3 inhibitor | 0.048 0.036 DBMET03516 | DBMET03516 | |
| 0.001 | 0.896 | 0.119 | Acyl-CoA dehydrogenase inhibitor | 0.119 0.013 DBMET03516 0.077 0.023 DBMET00960 | DBMET03516 | |
| 0.005 | 0.901 | 0.115 | Carbonic anhydrase XV inhibitor | 0.115 0.051 DBMET03516 | DBMET03516 | |
| 0.001 | 0.897 | 0.095 | Glutamate (mGluR5) agonist | 0.095 0.008 DBMET03516 | DBMET03516 | |
| 0.003 | 0.899 | 0.09 | Phosphodiesterase 1C inhibitor | 0.09 0.014 DBMET03516 | DBMET03516 | |
| 0.001 | 0.898 | 0.137 | Carbamoyl phosphate synthetase inhibitor | 0.137 0.013 DBMET03516 0.098 0.021 DBMET00960 | DBMET03516 | |
| 0.006 | 0.902 | 0.168 | Electrolyte absorption antagonist | 0.168 0.014 DBMET03516 0.108 0.048 DBMET00960 | DBMET03516 | |
| 0.004 | 0.901 | 0.219 | Neurotrophic factor | 0.219 0.02 DBMET03516 | DBMET03516 | |
| 0.003 | 0.9 | 0.196 | Diuretic | 0.196 0.046 DBMET03516 | DBMET03516 | |
| 0.007 | 0.905 | 0.343 | Cholesterol antagonist | 0.343 0.067 DBMET03516 0.209 0.157 DBMET00960 | DBMET03516 | |
| 0.001 | 0.898 | 0.044 | Protein kinase (CK1) epsilon inhibitor | 0.044 0.018 DBMET03516 | DBMET03516 | |
| 0.001 | 0.9 | 0.019 | Methylmalonyl-CoA mutase inhibitor | 0.019 0.012 DBMET03516 | DBMET03516 | |
| 0.009 | 0.909 | 0.143 | Polo-like kinase-2 inhibitor | 0.143 0.005 DBMET03516 | DBMET03516 | |
| 0.003 | 0.904 | 0.093 | Bromodomain-containing protein 4 inhibitor | 0.093 0.015 DBMET03516 | DBMET03516 | |
| 0.002 | 0.903 | 0.113 | 5 Hydroxytryptamine 4 antagonist | 0.113 0.005 DBMET03516 | DBMET03516 | |
| 0.003 | 0.904 | 0.074 | GABA B receptor agonist | 0.074 0.056 DBMET03516 | DBMET03516 | |
| 0.004 | 0.906 | 0.109 | Vascular endothelial growth factor 1 antagonist | 0.109 0.061 DBMET00960 | DBMET00960 | |
| 0.005 | 0.907 | 0.177 | DNA intercalator | 0.177 0.033 DBMET00960 | DBMET00960 | |
| 0.006 | 0.908 | 0.036 | ADAM10 endopeptidase inhibitor | 0.036 0.02 DBMET03516 | DBMET03516 | |
| 0.006 | 0.908 | 0.192 | Acetylcholine release stimulant | 0.192 0.005 DBMET03516 0.13 0.034 DBMET00960 | DBMET03516 | |
| 0.003 | 0.906 | 0.12 | Interleukin 1 beta converting enzyme inhibitor | 0.12 0.036 DBMET03516 | DBMET03516 | |
| 0.007 | 0.909 | 0.269 | MAP kinase 1 inhibitor | 0.269 0.213 DBMET03516 | DBMET03516 | |
| 0.001 | 0.904 | 0.048 | CDK4/cyclin D3 inhibitor | 0.048 0.008 DBMET03516 | DBMET03516 | |
| 0.005 | 0.908 | 0.078 | Glutamate (mGluR6) antagonist | 0.078 0.026 DBMET03516 0.067 0.046 DBMET00960 | DBMET03516 | |
| 0.003 | 0.907 | 0.071 | Cyclin-dependent kinase 4 inhibitor | 0.071 0.04 DBMET03516 | DBMET03516 | |
| 0.002 | 0.906 | 0.209 | Sodium channel (voltage-gated) blocker | 0.13 0.073 DBMET03516 0.209 0.026 DBMET00960 | DBMET00960 | |
| 0.001 | 0.904 | 0.042 | Lysine carboxypeptidase inhibitor | 0.042 0.01 DBMET03516 0.024 0.022 DBMET00960 | DBMET03516 | |
| 0.002 | 0.906 | 0.076 | Sphingosine kinase inhibitor | 0.076 0.019 DBMET03516 | DBMET03516 | |
| 0.027 | 0.931 | 0.548 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.548 0.017 DBMET03516 0.454 0.059 DBMET00960 | DBMET03516 | |
| 0.004 | 0.909 | 0.24 | Polo-like kinase-4 inhibitor | 0.24 0.009 DBMET03516 | DBMET03516 | |
| 0.018 | 0.923 | 0.237 | MAP-kinase-activated kinase 5 inhibitor | 0.237 0.068 DBMET03516 | DBMET03516 | |
| 0 | 0.906 | 0.018 | CXC chemokine 4 receptor agonist | 0.018 0.008 DBMET03516 | DBMET03516 | |
| 0.008 | 0.913 | 0.104 | Carbonic anhydrase III inhibitor | 0.104 0.057 DBMET03516 | DBMET03516 | |
| 0 | 0.907 | 0.056 | Arginase inhibitor | 0.056 0.012 DBMET03516 | DBMET03516 | |
| 0.001 | 0.909 | 0.144 | Glutamate decarboxylase inhibitor | 0.144 0.014 DBMET03516 0.099 0.03 DBMET00960 | DBMET03516 | |
| 0.003 | 0.911 | 0.281 | 5 Hydroxytryptamine agonist | 0.281 0.009 DBMET03516 | DBMET03516 | |
| 0.002 | 0.909 | 0.053 | Protein kinase (CK2) beta inhibitor | 0.053 0.006 DBMET03516 | DBMET03516 | |
| 0.002 | 0.911 | 0.063 | NMDA receptor agonist | 0.063 0.043 DBMET03516 | DBMET03516 | |
| 0.003 | 0.911 | 0.23 | I kappa B kinase epsilon inhibitor | 0.23 0.049 DBMET03516 | DBMET03516 | |
| 0.006 | 0.914 | 0.045 | ATM kinase inhibitor | 0.045 0.012 DBMET03516 | DBMET03516 | |
| 0.004 | 0.912 | 0.068 | CC chemokine 4 receptor antagonist | 0.068 0.011 DBMET03516 | DBMET03516 | |
| 0.004 | 0.913 | 0.501 | Spasmolytic | 0.438 0.033 DBMET03516 0.501 0.023 DBMET00960 | DBMET00960 | |
| 0.001 | 0.91 | 0.041 | Protease (Human cytomegalovirus) inhibitor | 0.041 0.005 DBMET03516 | DBMET03516 | |
| 0.006 | 0.916 | 0.089 | Viral attachment inhibitor | 0.089 0.034 DBMET03516 | DBMET03516 | |
| 0.003 | 0.913 | 0.118 | ErbB-4 antagonist | 0.118 0.031 DBMET03516 | DBMET03516 | |
| 0.002 | 0.912 | 0.236 | Neuronal nicotinic receptor antagonist | 0.236 0.007 DBMET03516 0.139 0.014 DBMET00960 | DBMET03516 | |
| 0.001 | 0.912 | 0.035 | Purinergic P2Y15 antagonist | 0.035 0.01 DBMET03516 0.027 0.023 DBMET00960 | DBMET03516 | |
| 0.002 | 0.914 | 0.166 | Calpain inhibitor | 0.166 0.154 DBMET03516 | DBMET03516 | |
| 0.001 | 0.913 | 0.162 | Histamine agonist | 0.162 0.005 DBMET03516 | DBMET03516 | |
| 0.002 | 0.914 | 0.071 | Cholesterol esterase inhibitor | 0.071 0.01 DBMET03516 | DBMET03516 | |
| 0.002 | 0.914 | 0.194 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | 0.194 0.104 DBMET03516 | DBMET03516 | |
| 0.003 | 0.915 | 0.064 | Bruton tyrosine kinase inhibitor | 0.064 0.031 DBMET03516 | DBMET03516 | |
| 0.005 | 0.918 | 0.104 | Phosphodiesterase 1B inhibitor | 0.104 0.013 DBMET03516 | DBMET03516 | |
| 0.001 | 0.914 | 0.099 | Pim-3 kinase inhibitor | 0.099 0.046 DBMET03516 | DBMET03516 | |
| 0.001 | 0.915 | 0.101 | Na+ K+ transporting ATPase inhibitor | 0.101 0.031 DBMET03516 0.084 0.047 DBMET00960 | DBMET03516 | |
| 0.003 | 0.917 | 0.265 | MAP kinase kinase 2 inhibitor | 0.265 0.048 DBMET03516 | DBMET03516 | |
| 0.006 | 0.92 | 0.126 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | 0.126 0.109 DBMET03516 | DBMET03516 | |
| 0.001 | 0.916 | 0.078 | Nerve growth factor antagonist | 0.078 0.004 DBMET03516 0.05 0.019 DBMET00960 | DBMET03516 | |
| 0.001 | 0.916 | 0.075 | Orexin receptor antagonist | 0.075 0.034 DBMET03516 | DBMET03516 | |
| 0.01 | 0.925 | 0.224 | Nav1.1 sodium channel blocker | 0.224 0.015 DBMET03516 | DBMET03516 | |
| 0.006 | 0.921 | 0.144 | Aminopeptidase B inhibitor | 0.144 0.04 DBMET03516 0.117 0.054 DBMET00960 | DBMET03516 | |
| 0.003 | 0.919 | 0.607 | 5 Hydroxytryptamine 1F antagonist | 0.607 0.004 DBMET03516 | DBMET03516 | |
| 0.008 | 0.925 | 0.208 | Nav1.3 sodium channel blocker | 0.208 0.022 DBMET03516 | DBMET03516 | |
| 0.011 | 0.928 | 0.604 | GABA C receptor rho-3 antagonist | 0.604 0.007 DBMET03516 0.485 0.03 DBMET00960 | DBMET03516 | |
| 0.003 | 0.92 | 0.098 | Ryanodine receptor antagonist | 0.098 0.004 DBMET03516 0.064 0.028 DBMET00960 | DBMET03516 | |
| 0.005 | 0.923 | 0.108 | Glutamate dehydrogenase inhibitor | 0.108 0.027 DBMET03516 0.088 0.038 DBMET00960 | DBMET03516 | |
| 0.001 | 0.919 | 0.022 | Microsomal triglyceride transfer protein inhibitor | 0.022 0.006 DBMET00960 | DBMET00960 | |
| 0.002 | 0.92 | 0.214 | Sigma receptor antagonist | 0.214 0.008 DBMET03516 | DBMET03516 | |
| 0.003 | 0.921 | 0.277 | 5 Hydroxytryptamine 1 agonist | 0.277 0.007 DBMET03516 | DBMET03516 | |
| 0.001 | 0.921 | 0.051 | Factor Xa inhibitor | 0.047 0.031 DBMET03516 0.051 0.028 DBMET00960 | DBMET00960 | |
| 0.003 | 0.923 | 0.204 | Fibroblast growth factor 1 antagonist | 0.12 0.043 DBMET03516 0.204 0.015 DBMET00960 | DBMET00960 | |
| 0.004 | 0.924 | 0.141 | Protein kinase C eta inhibitor | 0.141 0.009 DBMET03516 | DBMET03516 | |
| 0.01 | 0.93 | 0.141 | EphB2 antagonist | 0.141 0.139 DBMET03516 | DBMET03516 | |
| 0.001 | 0.922 | 0.039 | Epoxide hydrolase 1 inhibitor | 0.039 0.012 DBMET03516 | DBMET03516 | |
| 0.005 | 0.926 | 0.148 | Protein kinase C mu inhibitor | 0.148 0.027 DBMET03516 | DBMET03516 | |
| 0.04 | 0.961 | 0.262 | ErbB-1 antagonist | 0.262 0.046 DBMET03516 | DBMET03516 | |
| 0.004 | 0.925 | 0.465 | Ephrin antagonist | 0.465 0.005 DBMET00960 | DBMET00960 | |
| 0.001 | 0.923 | 0.091 | Glutamate (mGluR group I) agonist | 0.091 0.01 DBMET03516 | DBMET03516 | |
| 0.005 | 0.927 | 0.248 | Antipruritic | 0.248 0.025 DBMET03516 0.222 0.035 DBMET00960 | DBMET03516 | |
| 0.023 | 0.946 | 0.474 | 5 Hydroxytryptamine uptake stimulant | 0.474 0.005 DBMET03516 0.349 0.026 DBMET00960 | DBMET03516 | |
| 0.002 | 0.925 | 0.142 | Glycine receptor antagonist | 0.142 0.009 DBMET03516 0.095 0.037 DBMET00960 | DBMET03516 | |
| 0 | 0.923 | 0.021 | Alpha 2c adrenoreceptor agonist | 0.021 0.01 DBMET03516 | DBMET03516 | |
| 0.001 | 0.924 | 0.02 | Retinoid X beta receptor antagonist | 0.02 0.017 DBMET03516 | DBMET03516 | |
| 0.002 | 0.925 | 0.055 | CC chemokine 2 receptor antagonist | 0.055 0.038 DBMET03516 | DBMET03516 | |
| 0.003 | 0.926 | 0.134 | Mannose-6-phosphate isomerase inhibitor | 0.134 0.081 DBMET03516 | DBMET03516 | |
| 0 | 0.924 | 0.01 | Angiotensin AT2 receptor agonist | 0.01 0.008 DBMET03516 | DBMET03516 | |
| 0.001 | 0.925 | 0.119 | Granulocyte macrophage colony stimulating factor antagonist | 0.105 0.066 DBMET03516 0.119 0.054 DBMET00960 | DBMET00960 | |
| 0.003 | 0.927 | 0.02 | Histone-lysine N-methyltransferase EZH2 inhibitor | 0.02 0.016 DBMET03516 | DBMET03516 | |
| 0.001 | 0.926 | 0.047 | Dipeptidyl peptidase II inhibitor | 0.047 0.01 DBMET03516 | DBMET03516 | |
| 0.002 | 0.927 | 0.088 | Potassium channel intermediate-conductance Ca-activated blocker | 0.088 0.013 DBMET03516 0.055 0.054 DBMET00960 | DBMET03516 | |
| 0.003 | 0.928 | 0.128 | Gastric antisecretory | 0.128 0.038 DBMET03516 | DBMET03516 | |
| 0.002 | 0.929 | 0.028 | Complement factor 1s inhibitor | 0.028 0.012 DBMET03516 | DBMET03516 | |
| 0 | 0.927 | 0.064 | 5 Hydroxytryptamine 6 agonist | 0.064 0.004 DBMET03516 0.029 0.019 DBMET00960 | DBMET03516 | |
| 0.002 | 0.929 | 0.087 | Secretase beta inhibitor | 0.087 0.028 DBMET03516 | DBMET03516 | |
| 0.001 | 0.928 | 0.032 | Cyclin E2 inhibitor | 0.032 0.017 DBMET03516 | DBMET03516 | |
| 0.005 | 0.932 | 0.253 | GABA C receptor rho-2 antagonist | 0.253 0.011 DBMET03516 0.186 0.038 DBMET00960 | DBMET03516 | |
| 0.002 | 0.93 | 0.042 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.042 0.029 DBMET03516 0.041 0.031 DBMET00960 | DBMET03516 | |
| 0.002 | 0.929 | 0.212 | Nicotinic alpha4beta2 receptor antagonist | 0.212 0.004 DBMET03516 0.18 0.005 DBMET00960 | DBMET03516 | |
| 0.006 | 0.934 | 0.401 | Nootropic | 0.401 0.038 DBMET03516 0.308 0.071 DBMET00960 | DBMET03516 | |
| 0.002 | 0.93 | 0.134 | Insulin receptor antagonist | 0.134 0.034 DBMET03516 | DBMET03516 | |
| 0 | 0.929 | 0.082 | Nicotinic alpha4beta2 receptor agonist | 0.082 0.003 DBMET03516 0.037 0.01 DBMET00960 | DBMET03516 | |
| 0.003 | 0.931 | 0.031 | ATR kinase inhibitor | 0.031 0.027 DBMET03516 | DBMET03516 | |
| 0.004 | 0.933 | 0.139 | TRKC antagonist | 0.139 0.111 DBMET03516 | DBMET03516 | |
| 0 | 0.929 | 0.084 | Nicotinic alpha3beta4 receptor agonist | 0.084 0.003 DBMET03516 0.041 0.01 DBMET00960 | DBMET03516 | |
| 0.002 | 0.931 | 0.063 | Sigma 1 receptor antagonist | 0.063 0.009 DBMET03516 | DBMET03516 | |
| 0.002 | 0.931 | 0.332 | Ferrochelatase inhibitor | 0.332 0.005 DBMET03516 0.207 0.021 DBMET00960 | DBMET03516 | |
| 0.003 | 0.932 | 0.428 | Anesthetic general | 0.428 0.013 DBMET03516 0.181 0.086 DBMET00960 | DBMET03516 | |
| 0.002 | 0.931 | 0.117 | Glutamate (mGluR7) antagonist | 0.117 0.005 DBMET03516 0.076 0.033 DBMET00960 | DBMET03516 | |
| 0.002 | 0.932 | 0.321 | 5 Hydroxytryptamine 3A agonist | 0.321 0.003 DBMET03516 0.189 0.018 DBMET00960 | DBMET03516 | |
| 0.001 | 0.931 | 0.032 | Calcitonin receptor agonist | 0.032 0.025 DBMET03516 | DBMET03516 | |
| 0.004 | 0.933 | 0.313 | Abl kinase inhibitor | 0.313 0.01 DBMET00960 | DBMET00960 | |
| 0.002 | 0.932 | 0.092 | Alpha-mannosidase inhibitor | 0.092 0.008 DBMET03516 0.069 0.017 DBMET00960 | DBMET03516 | |
| 0.001 | 0.931 | 0.066 | Guanylate cyclase inhibitor | 0.066 0.007 DBMET03516 0.058 0.013 DBMET00960 | DBMET03516 | |
| 0.004 | 0.934 | 0.314 | Protein-tyrosine kinase (PTK, not ETK, WZC) inhibitor | 0.314 0.01 DBMET00960 | DBMET00960 | |
| 0.002 | 0.932 | 0.132 | Aminopeptidase I inhibitor | 0.132 0.016 DBMET03516 0.091 0.033 DBMET00960 | DBMET03516 | |
| 0.001 | 0.932 | 0.021 | Factor XIII inhibitor | 0.021 0.013 DBMET03516 | DBMET03516 | |
| 0.001 | 0.932 | 0.083 | Orexin receptor 1 antagonist | 0.083 0.03 DBMET03516 | DBMET03516 | |
| 0.001 | 0.932 | 0.075 | Mannosidase inhibitor | 0.075 0.01 DBMET03516 0.054 0.021 DBMET00960 | DBMET03516 | |
| 0.001 | 0.933 | 0.077 | Prolyl endopeptidase inhibitor | 0.077 0.012 DBMET03516 | DBMET03516 | |
| 0.003 | 0.935 | 0.095 | Cathepsin G inhibitor | 0.095 0.035 DBMET03516 | DBMET03516 | |
| 0.003 | 0.935 | 0.234 | GABA C receptor antagonist | 0.234 0.008 DBMET03516 0.168 0.022 DBMET00960 | DBMET03516 | |
| 0.001 | 0.934 | 0.093 | 5 Hydroxytryptamine 7 agonist | 0.093 0.008 DBMET03516 | DBMET03516 | |
| 0.001 | 0.934 | 0.253 | Histamine H1 receptor antagonist | 0.192 0.016 DBMET03516 0.253 0.009 DBMET00960 | DBMET00960 | |
| 0.001 | 0.934 | 0.08 | Fibroblast growth factor 3 antagonist | 0.08 0.051 DBMET03516 | DBMET03516 | |
| 0.001 | 0.935 | 0.086 | Catalase inhibitor | 0.086 0.044 DBMET03516 | DBMET03516 | |
| 0 | 0.934 | 0.034 | Orexin receptor 2 antagonist | 0.034 0.028 DBMET03516 | DBMET03516 | |
| 0.002 | 0.935 | 0.103 | GABA A receptor agonist | 0.103 0.035 DBMET03516 | DBMET03516 | |
| 0.004 | 0.938 | 0.254 | DNA damaging | 0.254 0.078 DBMET03516 0.16 0.158 DBMET00960 | DBMET03516 | |
| 0.007 | 0.942 | 0.172 | Transcription factor STAT6 inhibitor | 0.172 0.012 DBMET03516 | DBMET03516 | |
| 0.001 | 0.936 | 0.144 | 5 Hydroxytryptamine 3A antagonist | 0.144 0.005 DBMET03516 | DBMET03516 | |
| 0.037 | 0.972 | 0.12 | CC chemokine 6 receptor antagonist | 0.12 0.117 DBMET03516 | DBMET03516 | |
| 0.001 | 0.937 | 0.038 | Diamine oxidase inhibitor | 0.038 0.026 DBMET03516 | DBMET03516 | |
| 0.007 | 0.943 | 0.142 | Glutamate (mGluR7) agonist | 0.142 0.015 DBMET03516 0.095 0.07 DBMET00960 | DBMET03516 | |
| 0.004 | 0.94 | 0.571 | Polo-like kinase-3 inhibitor | 0.218 0.036 DBMET03516 0.571 0.003 DBMET00960 | DBMET00960 | |
| 0.006 | 0.942 | 0.674 | Proto-oncogene tyrosine-protein kinase Yes inhibitor | 0.2 0.042 DBMET03516 0.674 0.004 DBMET00960 | DBMET00960 | |
| 0.003 | 0.939 | 0.238 | 15-Lipoxygenase inhibitor | 0.238 0.175 DBMET03516 | DBMET03516 | |
| 0.001 | 0.938 | 0.127 | Tyrosine-protein kinase receptor antagonist | 0.127 0.08 DBMET03516 | DBMET03516 | |
| 0.005 | 0.941 | 0.901 | Analgesic | 0.59 0.029 DBMET03516 0.901 0.004 DBMET00960 | DBMET00960 | |
| 0 | 0.937 | 0.041 | Fumarate hydratase inhibitor | 0.041 0.018 DBMET03516 0.035 0.023 DBMET00960 | DBMET03516 | |
| 0.003 | 0.94 | 0.123 | Focal adhesion kinase 1 inhibitor | 0.123 0.017 DBMET03516 | DBMET03516 | |
| 0.003 | 0.941 | 0.183 | Dopamine transporter inhibitor | 0.183 0.005 DBMET03516 | DBMET03516 | |
| 0.003 | 0.94 | 0.031 | Phosphodiesterase 6G inhibitor | 0.031 0.007 DBMET03516 | DBMET03516 | |
| 0.003 | 0.94 | 0.031 | Phosphodiesterase 6H inhibitor | 0.031 0.007 DBMET03516 | DBMET03516 | |
| 0.022 | 0.959 | 0.303 | 5 Hydroxytryptamine 3E antagonist | 0.303 0.005 DBMET03516 0.244 0.019 DBMET00960 | DBMET03516 | |
| 0.001 | 0.939 | 0.085 | Cyclin-dependent kinase 9 inhibitor | 0.085 0.084 DBMET03516 | DBMET03516 | |
| 0.001 | 0.939 | 0.135 | Dopamine D2 antagonist | 0.128 0.026 DBMET03516 0.135 0.025 DBMET00960 | DBMET00960 | |
| 0.003 | 0.941 | 0.156 | Insulin sensitizer | 0.156 0.125 DBMET03516 | DBMET03516 | |
| 0.002 | 0.941 | 0.148 | Nitric-oxide synthase inhibitor | 0.148 0.023 DBMET03516 | DBMET03516 | |
| 0.001 | 0.939 | 0.029 | Thymidine phosphorylase inhibitor | 0.029 0.013 DBMET03516 | DBMET03516 | |
| 0.002 | 0.942 | 0.213 | GABA receptor agonist | 0.158 0.032 DBMET03516 0.213 0.015 DBMET00960 | DBMET00960 | |
| 0.001 | 0.94 | 0.096 | Biliverdin reductase inhibitor | 0.096 0.02 DBMET03516 0.078 0.027 DBMET00960 | DBMET03516 | |
| 0.001 | 0.94 | 0.018 | Antibiotic Anthracycline-like | 0.018 0.014 DBMET03516 | DBMET03516 | |
| 0.001 | 0.941 | 0.054 | Pim-2 kinase inhibitor | 0.054 0.038 DBMET03516 | DBMET03516 | |
| 0.003 | 0.943 | 0.11 | Caspase 3 inhibitor | 0.11 0.076 DBMET03516 | DBMET03516 | |
| 0 | 0.941 | 0.023 | Isoleucine-tRNA ligase inhibitor | 0.023 0.015 DBMET03516 | DBMET03516 | |
| 0.009 | 0.949 | 0.341 | 5 Hydroxytryptamine release inhibitor | 0.341 0.123 DBMET03516 0.257 0.218 DBMET00960 | DBMET03516 | |
| 0.001 | 0.942 | 0.106 | Cyclin-dependent kinase 6 inhibitor | 0.106 0.009 DBMET03516 | DBMET03516 | |
| 0.001 | 0.941 | 0.054 | Adenosine A2a receptor antagonist | 0.054 0.05 DBMET03516 | DBMET03516 | |
| 0.001 | 0.941 | 0.059 | Ornithine carbamoyltransferase inhibitor | 0.059 0.032 DBMET03516 0.05 0.039 DBMET00960 | DBMET03516 | |
| 0 | 0.941 | 0.035 | NMDA receptor phencyclidine site antagonist | 0.035 0.004 DBMET03516 | DBMET03516 | |
| 0.006 | 0.947 | 0.151 | 3C-like protease (Human coronavirus) inhibitor | 0.151 0.099 DBMET03516 | DBMET03516 | |
| 0.021 | 0.962 | 0.136 | Cyclin-dependent kinase 3 inhibitor | 0.136 0.134 DBMET03516 | DBMET03516 | |
| 0.002 | 0.943 | 0.108 | Lysine-specific demethylase 1A inhibitor | 0.108 0.005 DBMET03516 | DBMET03516 | |
| 0.004 | 0.946 | 0.099 | Granulocyte macrophage colony stimulating factor agonist | 0.099 0.036 DBMET03516 0.084 0.065 DBMET00960 | DBMET03516 | |
| 0.001 | 0.943 | 0.047 | Toll-Like receptor 2 agonist | 0.047 0.025 DBMET03516 | DBMET03516 | |
| 0.014 | 0.956 | 0.13 | CC chemokine 5 receptor agonist | 0.13 0.005 DBMET03516 0.088 0.041 DBMET00960 | DBMET03516 | |
| 0.001 | 0.944 | 0.15 | Dopamine antagonist | 0.15 0.026 DBMET03516 0.135 0.028 DBMET00960 | DBMET03516 | |
| 0.002 | 0.944 | 0.096 | Bcr-Abl kinase inhibitor | 0.096 0.045 DBMET03516 | DBMET03516 | |
| 0.001 | 0.944 | 0.042 | Histone deacetylase 9 inhibitor | 0.042 0.023 DBMET03516 | DBMET03516 | |
| 0.001 | 0.944 | 0.072 | TRPA1 antagonist | 0.072 0.03 DBMET03516 | DBMET03516 | |
| 0.008 | 0.951 | 0.157 | Adenylate kinase inhibitor | 0.157 0.024 DBMET03516 0.132 0.035 DBMET00960 | DBMET03516 | |
| 0.001 | 0.945 | 0.233 | 5 Hydroxytryptamine antagonist | 0.233 0.027 DBMET03516 0.146 0.051 DBMET00960 | DBMET03516 | |
| 0 | 0.944 | 0.016 | CDK2/cyclin A3 inhibitor | 0.016 0.011 DBMET03516 | DBMET03516 | |
| 0 | 0.945 | 0.021 | Apolipoprotein B inhibitor | 0.021 0.012 DBMET03516 | DBMET03516 | |
| 0.003 | 0.948 | 0.116 | c-Src kinase inhibitor | 0.116 0.078 DBMET03516 | DBMET03516 | |
| 0.001 | 0.945 | 0.051 | HCV NS5B polymerase inhibitor | 0.051 0.009 DBMET00960 | DBMET00960 | |
| 0.003 | 0.947 | 0.027 | Phosphodiesterase 6A inhibitor | 0.027 0.01 DBMET03516 | DBMET03516 | |
| 0.003 | 0.947 | 0.286 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.286 0.028 DBMET03516 0.187 0.085 DBMET00960 | DBMET03516 | |
| 0 | 0.945 | 0.029 | Hypoxanthine phosphoribosyltransferase inhibitor | 0.029 0.019 DBMET03516 | DBMET03516 | |
| 0.001 | 0.946 | 0.237 | MAO A inhibitor | 0.088 0.073 DBMET03516 0.237 0.023 DBMET00960 | DBMET00960 | |
| 0.003 | 0.948 | 0.236 | Alpha 2b adrenoreceptor antagonist | 0.236 0.017 DBMET03516 0.138 0.045 DBMET00960 | DBMET03516 | |
| 0.001 | 0.946 | 0.064 | 11-Beta-hydroxysteroid dehydrogenase 2 inhibitor | 0.064 0.006 DBMET03516 | DBMET03516 | |
| 0.001 | 0.946 | 0.108 | Alcohol oxidase inhibitor | 0.108 0.016 DBMET03516 0.085 0.022 DBMET00960 | DBMET03516 | |
| 0 | 0.946 | 0.019 | Cyclin D2 inhibitor | 0.019 0.004 DBMET03516 | DBMET03516 | |
| 0 | 0.947 | 0.069 | Dopamine D5 agonist | 0.069 0.009 DBMET03516 0.052 0.016 DBMET00960 | DBMET03516 | |
| 0.002 | 0.948 | 0.039 | Retinoid X alpha receptor antagonist | 0.039 0.016 DBMET03516 | DBMET03516 | |
| 0.005 | 0.951 | 0.213 | Alpha 2c adrenoreceptor antagonist | 0.213 0.015 DBMET03516 0.122 0.048 DBMET00960 | DBMET03516 | |
| 0.001 | 0.948 | 0.117 | TRKA antagonist | 0.117 0.07 DBMET03516 | DBMET03516 | |
| 0.002 | 0.949 | 0.112 | Inducible nitric-oxide synthase inhibitor | 0.112 0.028 DBMET03516 | DBMET03516 | |
| 0.001 | 0.949 | 0.141 | Bromodomain-containing protein 2 inhibitor | 0.141 0.012 DBMET03516 | DBMET03516 | |
| 0.001 | 0.948 | 0.066 | Histamine H1 receptor agonist | 0.066 0.005 DBMET03516 0.046 0.025 DBMET00960 | DBMET03516 | |
| 0.001 | 0.949 | 0.086 | Epithelial sodium channel blocker | 0.086 0.01 DBMET03516 | DBMET03516 | |
| 0.001 | 0.949 | 0.086 | Potassium channel (Voltage-sensitive) activator | 0.086 0.076 DBMET03516 | DBMET03516 | |
| 0.001 | 0.95 | 0.042 | CF transmembrane conductance regulator antagonist | 0.042 0.019 DBMET03516 | DBMET03516 | |
| 0.005 | 0.953 | 0.144 | NADH dehydrogenase inhibitor | 0.144 0.019 DBMET03516 0.107 0.037 DBMET00960 | DBMET03516 | |
| 0.004 | 0.953 | 0.129 | Vanilloid 4 agonist | 0.129 0.005 DBMET03516 0.098 0.018 DBMET00960 | DBMET03516 | |
| 0.002 | 0.951 | 0.042 | Glycine transporter 1 inhibitor | 0.042 0.019 DBMET03516 | DBMET03516 | |
| 0.016 | 0.965 | 0.102 | Transforming growth factor beta 3 antagonist | 0.086 0.046 DBMET03516 0.102 0.021 DBMET00960 | DBMET00960 | |
| 0.002 | 0.951 | 0.223 | Falcipain 3 inhibitor | 0.223 0.012 DBMET03516 0.096 0.075 DBMET00960 | DBMET03516 | |
| 0.005 | 0.954 | 0.151 | 5 Hydroxytryptamine 1B agonist | 0.151 0.004 DBMET03516 | DBMET03516 | |
| 0.003 | 0.952 | 0.043 | Protein kinase C beta II inhibitor | 0.043 0.009 DBMET03516 | DBMET03516 | |
| 0.002 | 0.952 | 0.387 | 5 Hydroxytryptamine 1E antagonist | 0.387 0.005 DBMET03516 0.267 0.056 DBMET00960 | DBMET03516 | |
| 0.001 | 0.951 | 0.256 | Dopamine D1 antagonist | 0.209 0.01 DBMET03516 0.256 0.008 DBMET00960 | DBMET00960 | |
| 0.002 | 0.952 | 0.032 | Dipeptidyl peptidase I inhibitor | 0.032 0.019 DBMET03516 | DBMET03516 | |
| 0 | 0.95 | 0.027 | Glutamate (mGluR1a) agonist | 0.027 0.01 DBMET03516 | DBMET03516 | |
| 0.001 | 0.951 | 0.182 | Activin receptor-like kinase 2 inhibitor | 0.182 0.045 DBMET03516 | DBMET03516 | |
| 0.002 | 0.952 | 0.043 | Retinoid X receptor antagonist | 0.043 0.019 DBMET03516 | DBMET03516 | |
| 0.001 | 0.952 | 0.043 | Vanilloid 4 antagonist | 0.043 0.009 DBMET03516 | DBMET03516 | |
| 0.004 | 0.954 | 0.276 | Adrenaline uptake inhibitor | 0.219 0.005 DBMET03516 0.276 0.005 DBMET00960 | DBMET00960 | |
| 0.005 | 0.955 | 0.048 | Topoisomerase II beta inhibitor | 0.048 0.035 DBMET03516 | DBMET03516 | |
| 0.022 | 0.972 | 0.216 | Nitric-oxide synthase stimulant | 0.216 0.065 DBMET03516 0.207 0.077 DBMET00960 | DBMET03516 | |
| 0.001 | 0.952 | 0.177 | 5 Hydroxytryptamine 2A antagonist | 0.177 0.023 DBMET03516 0.156 0.027 DBMET00960 | DBMET03516 | |
| 0.002 | 0.953 | 0.199 | Cyclin-dependent kinase 8 inhibitor | 0.199 0.036 DBMET03516 | DBMET03516 | |
| 0.002 | 0.953 | 0.164 | UDP-glucose 4-epimerase inhibitor | 0.164 0.025 DBMET03516 0.141 0.032 DBMET00960 | DBMET03516 | |
| 0 | 0.951 | 0.026 | Cyclin T1 inhibitor | 0.026 0.007 DBMET03516 | DBMET03516 | |
| 0.003 | 0.954 | 0.136 | Phosphodiesterase I inhibitor | 0.136 0.021 DBMET03516 | DBMET03516 | |
| 0.001 | 0.952 | 0.123 | Dopamine D3 antagonist | 0.123 0.019 DBMET03516 0.059 0.046 DBMET00960 | DBMET03516 | |
| 0.003 | 0.954 | 0.366 | 5 Hydroxytryptamine 7 antagonist | 0.366 0.005 DBMET03516 | DBMET03516 | |
| 0.001 | 0.952 | 0.037 | NMDA receptor subunit 3A antagonist | 0.037 0.028 DBMET03516 | DBMET03516 | |
| 0.002 | 0.954 | 0.137 | Caspase 7 inhibitor | 0.137 0.01 DBMET03516 | DBMET03516 | |
| 0.003 | 0.956 | 0.15 | Thiol protease inhibitor | 0.15 0.069 DBMET03516 | DBMET03516 | |
| 0.001 | 0.953 | 0.072 | Vascular adhesion protein 1 inhibitor | 0.072 0.005 DBMET03516 | DBMET03516 | |
| 0 | 0.953 | 0.089 | Alpha 1d adrenoreceptor agonist | 0.089 0.004 DBMET03516 0.054 0.014 DBMET00960 | DBMET03516 | |
| 0.004 | 0.957 | 0.146 | Tyrosine kinase inhibitor | 0.146 0.092 DBMET03516 | DBMET03516 | |
| 0.008 | 0.961 | 0.196 | Ca2+-transporting ATPase inhibitor | 0.196 0.004 DBMET03516 0.167 0.015 DBMET00960 | DBMET03516 | |
| 0.001 | 0.954 | 0.104 | Histidine decarboxylase inhibitor | 0.104 0.03 DBMET03516 0.063 0.058 DBMET00960 | DBMET03516 | |
| 0.005 | 0.958 | 0.199 | Cardiotonic | 0.199 0.12 DBMET03516 | DBMET03516 | |
| 0 | 0.953 | 0.093 | 5 Hydroxytryptamine 1D agonist | 0.093 0.004 DBMET03516 | DBMET03516 | |
| 0.001 | 0.954 | 0.066 | Glutamate (mGluR1a) antagonist | 0.066 0.013 DBMET03516 | DBMET03516 | |
| 0.001 | 0.954 | 0.043 | Peptide deformylase inhibitor | 0.043 0.013 DBMET03516 | DBMET03516 | |
| 0.001 | 0.955 | 0.07 | AMPA 4 receptor antagonist | 0.07 0.008 DBMET03516 | DBMET03516 | |
| 0.001 | 0.955 | 0.123 | CYP2A6 inhibitor | 0.123 0.026 DBMET03516 | DBMET03516 | |
| 0.003 | 0.957 | 0.169 | ALK inhibitor | 0.169 0.016 DBMET03516 | DBMET03516 | |
| 0.003 | 0.956 | 0.049 | Phosphodiesterase 6B inhibitor | 0.049 0.007 DBMET03516 | DBMET03516 | |
| 0.005 | 0.958 | 0.195 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | 0.195 0.078 DBMET03516 | DBMET03516 | |
| 0.001 | 0.955 | 0.114 | Histamine H4 receptor antagonist | 0.114 0.004 DBMET03516 0.044 0.043 DBMET00960 | DBMET03516 | |
| 0.002 | 0.955 | 0.078 | Adrenaline agonist | 0.078 0.06 DBMET03516 | DBMET03516 | |
| 0.001 | 0.955 | 0.21 | Focal adhesion kinase 2 inhibitor | 0.21 0.062 DBMET03516 | DBMET03516 | |
| 0.001 | 0.956 | 0.087 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.087 0.026 DBMET03516 0.079 0.039 DBMET00960 | DBMET03516 | |
| 0.004 | 0.959 | 0.09 | D-Ala-D-Ala ligase inhibitor | 0.09 0.045 DBMET03516 | DBMET03516 | |
| 0.001 | 0.956 | 0.061 | Histone deacetylase SIRT3 inhibitor | 0.061 0.047 DBMET03516 | DBMET03516 | |
| 0.003 | 0.958 | 0.312 | 5 Hydroxytryptamine uptake inhibitor | 0.312 0.005 DBMET03516 | DBMET03516 | |
| 0.004 | 0.959 | 0.152 | Src kinase inhibitor | 0.152 0.082 DBMET00960 | DBMET00960 | |
| 0.001 | 0.956 | 0.05 | NMDA receptor subunit 3B antagonist | 0.05 0.025 DBMET03516 | DBMET03516 | |
| 0.001 | 0.956 | 0.133 | Alpha 2 adrenoreceptor agonist | 0.133 0.008 DBMET03516 | DBMET03516 | |
| 0.004 | 0.959 | 0.08 | Phosphodiesterase 5A inhibitor | 0.068 0.052 DBMET03516 0.08 0.04 DBMET00960 | DBMET00960 | |
| 0.004 | 0.96 | 0.128 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.128 0.035 DBMET03516 0.114 0.043 DBMET00960 | DBMET03516 | |
| 0 | 0.956 | 0.009 | Corticotropin releasing factor antagonist | 0.009 0.008 DBMET03516 | DBMET03516 | |
| 0.001 | 0.957 | 0.153 | Alpha adrenoreceptor agonist | 0.153 0.016 DBMET03516 | DBMET03516 | |
| 0.005 | 0.96 | 0.1 | Multidrug resistance-associated protein 1 inhibitor | 0.1 0.079 DBMET03516 | DBMET03516 | |
| 0.001 | 0.957 | 0.038 | Factor XIIIa inhibitor | 0.038 0.026 DBMET03516 | DBMET03516 | |
| 0.001 | 0.957 | 0.05 | Adenosine A1 receptor antagonist | 0.05 0.049 DBMET03516 | DBMET03516 | |
| 0.001 | 0.958 | 0.131 | MAP kinase kinase inhibitor | 0.131 0.064 DBMET03516 | DBMET03516 | |
| 0.008 | 0.964 | 0.081 | Calcium channel P-type blocker | 0.081 0.014 DBMET03516 0.062 0.049 DBMET00960 | DBMET03516 | |
| 0.001 | 0.957 | 0.079 | EphB4 antagonist | 0.051 0.049 DBMET03516 0.079 0.024 DBMET00960 | DBMET00960 | |
| 0 | 0.957 | 0.014 | Lysophosphatidic acid receptor 3 agonist | 0.014 0.009 DBMET03516 | DBMET03516 | |
| 0.001 | 0.958 | 0.12 | Alpha 1 adrenoreceptor agonist | 0.12 0.013 DBMET03516 | DBMET03516 | |
| 0.003 | 0.959 | 0.15 | Nav1.5 sodium channel blocker | 0.15 0.027 DBMET03516 | DBMET03516 | |
| 0.003 | 0.96 | 0.076 | Phosphodiesterase V inhibitor | 0.069 0.053 DBMET03516 0.076 0.045 DBMET00960 | DBMET00960 | |
| 0.002 | 0.959 | 0.053 | Dihydroorotate oxidase inhibitor | 0.053 0.043 DBMET03516 | DBMET03516 | |
| 0.001 | 0.958 | 0.027 | Glucosylceramidase stimulant | 0.027 0.021 DBMET03516 | DBMET03516 | |
| 0.002 | 0.96 | 0.167 | Neuropeptide Y1 antagonist | 0.167 0.042 DBMET03516 | DBMET03516 | |
| 0.002 | 0.96 | 0.061 | Cytokine production stimulant | 0.061 0.012 DBMET03516 | DBMET03516 | |
| 0.001 | 0.959 | 0.069 | Cyclin A1 inhibitor | 0.069 0.023 DBMET03516 | DBMET03516 | |
| 0 | 0.959 | 0.13 | 5 Hydroxytryptamine 6 antagonist | 0.13 0.009 DBMET03516 | DBMET03516 | |
| 0.001 | 0.96 | 0.251 | MAO inhibitor | 0.105 0.085 DBMET03516 0.251 0.028 DBMET00960 | DBMET00960 | |
| 0.001 | 0.959 | 0.037 | Histone deacetylase 7 inhibitor | 0.037 0.025 DBMET03516 | DBMET03516 | |
| 0.001 | 0.959 | 0.071 | Cyclin A inhibitor | 0.071 0.037 DBMET03516 | DBMET03516 | |
| 0.001 | 0.96 | 0.077 | Cyclin A2 inhibitor | 0.077 0.034 DBMET03516 | DBMET03516 | |
| 0 | 0.959 | 0.099 | Dopamine D4 antagonist | 0.099 0.026 DBMET03516 | DBMET03516 | |
| 0.001 | 0.959 | 0.115 | 5 Hydroxytryptamine 1A antagonist | 0.115 0.027 DBMET03516 | DBMET03516 | |
| 0.002 | 0.961 | 0.071 | Protease 3C (Human rhinovirus) inhibitor | 0.071 0.035 DBMET03516 | DBMET03516 | |
| 0.002 | 0.961 | 0.234 | 5 Hydroxytryptamine 2B antagonist | 0.234 0.021 DBMET03516 0.174 0.032 DBMET00960 | DBMET03516 | |
| 0.001 | 0.96 | 0.22 | 5 Hydroxytryptamine 2 antagonist | 0.22 0.026 DBMET03516 0.208 0.028 DBMET00960 | DBMET03516 | |
| 0.004 | 0.963 | 0.216 | Antiadrenergic | 0.202 0.024 DBMET03516 0.216 0.021 DBMET00960 | DBMET00960 | |
| 0.001 | 0.961 | 0.34 | Toll-Like receptor 9 antagonist | 0.34 0.008 DBMET03516 | DBMET03516 | |
| 0.001 | 0.96 | 0.028 | Lysophosphatidic acid receptor 1 agonist | 0.028 0.013 DBMET03516 0.023 0.022 DBMET00960 | DBMET03516 | |
| 0.001 | 0.96 | 0.145 | 5 Hydroxytryptamine 1 antagonist | 0.145 0.025 DBMET03516 | DBMET03516 | |
| 0.001 | 0.96 | 0.162 | 5 Hydroxytryptamine 1D antagonist | 0.162 0.01 DBMET03516 | DBMET03516 | |
| 0.004 | 0.964 | 0.104 | Corticotropin releasing factor 2 receptor antagonist | 0.104 0.005 DBMET03516 | DBMET03516 | |
| 0.002 | 0.962 | 0.315 | Anticonvulsant | 0.315 0.037 DBMET03516 | DBMET03516 | |
| 0.006 | 0.966 | 0.062 | Phosphodiesterase 6C inhibitor | 0.062 0.007 DBMET03516 | DBMET03516 | |
| 0.002 | 0.962 | 0.081 | Heat shock protein 90 beta antagonist | 0.081 0.02 DBMET03516 | DBMET03516 | |
| 0.004 | 0.965 | 0.182 | Tumour necrosis factor antagonist | 0.182 0.065 DBMET03516 | DBMET03516 | |
| 0.001 | 0.962 | 0.061 | Carbonic anhydrase stimulant | 0.061 0.039 DBMET03516 | DBMET03516 | |
| 0.009 | 0.97 | 0.491 | Caspase 9 stimulant | 0.491 0.063 DBMET03516 0.364 0.134 DBMET00960 | DBMET03516 | |
| 0 | 0.961 | 0.048 | Sigma 2 receptor antagonist | 0.048 0.01 DBMET03516 | DBMET03516 | |
| 0.001 | 0.962 | 0.076 | Enoyl-[acyl-carrier-protein] reductase inhibitor | 0.076 0.022 DBMET03516 | DBMET03516 | |
| 0.003 | 0.964 | 0.06 | Protein kinase C theta inhibitor | 0.06 0.037 DBMET03516 | DBMET03516 | |
| 0.01 | 0.971 | 0.322 | Interleukin agonist | 0.322 0.038 DBMET03516 0.218 0.104 DBMET00960 | DBMET03516 | |
| 0.001 | 0.962 | 0.074 | Aconitate hydratase inhibitor | 0.074 0.016 DBMET03516 0.06 0.026 DBMET00960 | DBMET03516 | |
| 0.004 | 0.965 | 0.213 | Adrenaline antagonist | 0.197 0.024 DBMET03516 0.213 0.021 DBMET00960 | DBMET00960 | |
| 0.001 | 0.962 | 0.055 | Cannabinoid CB2 receptor agonist | 0.055 0.037 DBMET03516 | DBMET03516 | |
| 0.001 | 0.963 | 0.126 | 5 Hydroxytryptamine 5A antagonist | 0.126 0.01 DBMET03516 | DBMET03516 | |
| 0.005 | 0.967 | 0.145 | CF transmembrane conductance regulator agonist | 0.145 0.085 DBMET03516 | DBMET03516 | |
| 0 | 0.962 | 0.037 | MAP3K8 inhibitor | 0.037 0.009 DBMET03516 | DBMET03516 | |
| 0 | 0.962 | 0.099 | Toll-Like receptor 8 antagonist | 0.099 0.009 DBMET03516 | DBMET03516 | |
| 0.001 | 0.963 | 0.056 | Adenosine uptake inhibitor | 0.056 0.004 DBMET03516 0.034 0.025 DBMET00960 | DBMET03516 | |
| 0 | 0.962 | 0.057 | Myristoyl transferase inhibitor | 0.057 0.004 DBMET03516 | DBMET03516 | |
| 0.001 | 0.963 | 0.101 | Glutamate receptor agonist | 0.101 0.036 DBMET03516 | DBMET03516 | |
| 0.002 | 0.964 | 0.113 | Interferon agonist | 0.113 0.02 DBMET03516 | DBMET03516 | |
| 0.001 | 0.963 | 0.168 | Protein kinase C zeta inhibitor | 0.168 0.016 DBMET03516 | DBMET03516 | |
| 0.001 | 0.963 | 0.122 | 5 Hydroxytryptamine 5 antagonist | 0.122 0.011 DBMET03516 | DBMET03516 | |
| 0.001 | 0.964 | 0.172 | Dopamine uptake inhibitor | 0.172 0.008 DBMET03516 | DBMET03516 | |
| 0.001 | 0.964 | 0.13 | MAP kinase kinase 1 inhibitor | 0.13 0.026 DBMET03516 | DBMET03516 | |
| 0 | 0.963 | 0.034 | Glucose-dependent insulinotropic receptor agonist | 0.034 0.025 DBMET03516 | DBMET03516 | |
| 0.001 | 0.963 | 0.127 | Phosphofructokinase-1 inhibitor | 0.127 0.023 DBMET03516 0.106 0.03 DBMET00960 | DBMET03516 | |
| 0.001 | 0.964 | 0.04 | MAP3K5 inhibitor | 0.04 0.026 DBMET03516 | DBMET03516 | |
| 0.002 | 0.965 | 0.055 | Adenosine deaminase inhibitor | 0.053 0.027 DBMET03516 0.055 0.026 DBMET00960 | DBMET00960 | |
| 0.003 | 0.966 | 0.063 | Purinergic P2X1 antagonist | 0.063 0.039 DBMET03516 | DBMET03516 | |
| 0 | 0.963 | 0.016 | Imidazoline I2 receptor antagonist | 0.016 0.004 DBMET03516 | DBMET03516 | |
| 0.001 | 0.964 | 0.062 | Calcium channel T-type blocker | 0.062 0.035 DBMET03516 | DBMET03516 | |
| 0.001 | 0.963 | 0.084 | Alpha 1d adrenoreceptor antagonist | 0.084 0.028 DBMET03516 | DBMET03516 | |
| 0.001 | 0.964 | 0.045 | Tryptophan 5 hydroxylase inhibitor | 0.045 0.009 DBMET03516 | DBMET03516 | |
| 0.002 | 0.965 | 0.097 | Cyclin D1 inhibitor | 0.097 0.009 DBMET03516 | DBMET03516 | |
| 0.004 | 0.967 | 0.212 | Peroxidase inhibitor | 0.212 0.056 DBMET03516 0.117 0.103 DBMET00960 | DBMET03516 | |
| 0.003 | 0.966 | 0.268 | Prolactin inhibitor | 0.268 0.004 DBMET03516 0.16 0.019 DBMET00960 | DBMET03516 | |
| 0 | 0.964 | 0.057 | Geranyltranstransferase inhibitor | 0.057 0.016 DBMET03516 | DBMET03516 | |
| 0 | 0.963 | 0.017 | Telomerase stimulant | 0.017 0.011 DBMET03516 | DBMET03516 | |
| 0.003 | 0.966 | 0.105 | MAP kinase kinase 7 inhibitor | 0.105 0.009 DBMET03516 0.084 0.036 DBMET00960 | DBMET03516 | |
| 0.003 | 0.966 | 0.192 | Neurotensin receptor agonist | 0.192 0.039 DBMET03516 0.155 0.091 DBMET00960 | DBMET03516 | |
| 0.002 | 0.966 | 0.096 | AMP-activated protein kinase stimulant | 0.096 0.076 DBMET03516 | DBMET03516 | |
| 0 | 0.964 | 0.081 | Melanin-concentrating hormone receptor 1 antagonist | 0.081 0.02 DBMET03516 | DBMET03516 | |
| 0.002 | 0.966 | 0.213 | Succinate dehydrogenase inhibitor | 0.213 0.04 DBMET03516 0.196 0.052 DBMET00960 | DBMET03516 | |
| 0.002 | 0.966 | 0.118 | Phosphodiesterase 1A inhibitor | 0.118 0.007 DBMET03516 | DBMET03516 | |
| 0 | 0.964 | 0.018 | Complement factor D inhibitor | 0.018 0.013 DBMET03516 | DBMET03516 | |
| 0.002 | 0.966 | 0.194 | Alpha 2a adrenoreceptor antagonist | 0.194 0.015 DBMET03516 0.074 0.053 DBMET00960 | DBMET03516 | |
| 0.001 | 0.965 | 0.183 | Cystathionine beta-synthase inhibitor | 0.183 0.029 DBMET03516 0.103 0.073 DBMET00960 | DBMET03516 | |
| 0.002 | 0.966 | 0.202 | Alpha 2 adrenoreceptor antagonist | 0.202 0.017 DBMET03516 | DBMET03516 | |
| 0 | 0.965 | 0.023 | Kainate receptor 1 antagonist | 0.023 0.013 DBMET03516 | DBMET03516 | |
| 0.001 | 0.966 | 0.059 | Beta 2 adrenoreceptor agonist | 0.059 0.053 DBMET03516 | DBMET03516 | |
| 0.001 | 0.965 | 0.078 | Argininosuccinate synthase inhibitor | 0.078 0.026 DBMET03516 0.064 0.034 DBMET00960 | DBMET03516 | |
| 0.001 | 0.966 | 0.066 | Ceramide glucosyltransferase inhibitor | 0.066 0.004 DBMET03516 0.032 0.031 DBMET00960 | DBMET03516 | |
| 0 | 0.965 | 0.036 | AMPA 3 receptor antagonist | 0.036 0.016 DBMET03516 | DBMET03516 | |
| 0 | 0.965 | 0.088 | Leucine-rich repeat kinase 2 inhibitor | 0.088 0.051 DBMET03516 | DBMET03516 | |
| 0 | 0.965 | 0.042 | Imidazoline I1 receptor antagonist | 0.042 0.004 DBMET03516 0.019 0.017 DBMET00960 | DBMET03516 | |
| 0.002 | 0.967 | 0.165 | Calcium antagonist | 0.165 0.019 DBMET03516 0.075 0.069 DBMET00960 | DBMET03516 | |
| 0.001 | 0.966 | 0.097 | Insulin like growth factor 1 antagonist | 0.097 0.044 DBMET03516 | DBMET03516 | |
| 0.002 | 0.967 | 0.07 | Glucose-6-phosphate isomerase inhibitor | 0.07 0.012 DBMET03516 0.061 0.018 DBMET00960 | DBMET03516 | |
| 0.001 | 0.966 | 0.087 | Interleukin-1 receptor-associated protein kinase 4 inhibitor | 0.087 0.06 DBMET03516 | DBMET03516 | |
| 0.001 | 0.966 | 0.102 | Insulin growth factor antagonist | 0.102 0.045 DBMET03516 | DBMET03516 | |
| 0.002 | 0.968 | 0.18 | Sphingosine 1-phosphate receptor 5 antagonist | 0.18 0.024 DBMET03516 0.126 0.11 DBMET00960 | DBMET03516 | |
| 0.001 | 0.967 | 0.08 | Phenylalanine 4-hydroxylase inhibitor | 0.08 0.038 DBMET03516 | DBMET03516 | |
| 0.001 | 0.967 | 0.061 | Cannabinoid receptor agonist | 0.061 0.048 DBMET03516 | DBMET03516 | |
| 0.01 | 0.976 | 0.188 | Heat shock protein 70 antagonist | 0.188 0.009 DBMET03516 0.135 0.096 DBMET00960 | DBMET03516 | |
| 0.001 | 0.967 | 0.05 | Benzodiazepine antagonist | 0.05 0.027 DBMET03516 | DBMET03516 | |
| 0.001 | 0.967 | 0.079 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.079 0.021 DBMET03516 0.056 0.039 DBMET00960 | DBMET03516 | |
| 0.001 | 0.967 | 0.065 | Glutamate (mGluR group III) antagonist | 0.065 0.011 DBMET03516 | DBMET03516 | |
| 0.004 | 0.97 | 0.08 | Cyclin B3 inhibitor | 0.08 0.038 DBMET03516 | DBMET03516 | |
| 0.008 | 0.975 | 0.466 | Tyrosine 3 hydroxylase inhibitor | 0.466 0.004 DBMET03516 0.353 0.015 DBMET00960 | DBMET03516 | |
| 0.001 | 0.967 | 0.063 | Syk tyrosine kinase inhibitor | 0.063 0.057 DBMET03516 | DBMET03516 | |
| 0.001 | 0.967 | 0.1 | MAP kinase kinase kinase inhibitor | 0.1 0.066 DBMET03516 | DBMET03516 | |
| 0.001 | 0.967 | 0.02 | Toll-Like receptor 8 agonist | 0.02 0.015 DBMET03516 | DBMET03516 | |
| 0.009 | 0.976 | 0.368 | Calcium channel activator | 0.368 0.039 DBMET03516 0.307 0.084 DBMET00960 | DBMET03516 | |
| 0.002 | 0.969 | 0.059 | 5 Hydroxytryptamine 2C agonist | 0.059 0.021 DBMET03516 | DBMET03516 | |
| 0.001 | 0.968 | 0.133 | Porphobilinogen synthase inhibitor | 0.133 0.024 DBMET03516 0.097 0.037 DBMET00960 | DBMET03516 | |
| 0 | 0.967 | 0.083 | Histamine H3 receptor antagonist | 0.083 0.015 DBMET03516 | DBMET03516 | |
| 0.001 | 0.968 | 0.055 | Cannabinoid CB1 receptor agonist | 0.055 0.047 DBMET03516 | DBMET03516 | |
| 0.003 | 0.97 | 0.295 | Antithrombotic | 0.295 0.091 DBMET03516 | DBMET03516 | |
| 0.003 | 0.97 | 0.153 | Nicotinic alpha3beta2 receptor antagonist | 0.153 0.004 DBMET03516 0.153 0.004 DBMET00960 | DBMET00960 | |
| 0.001 | 0.968 | 0.06 | Glutamate (mGluR1) antagonist | 0.06 0.039 DBMET03516 | DBMET03516 | |
| 0 | 0.968 | 0.03 | Vanilloid 2 agonist | 0.03 0.01 DBMET03516 0.025 0.017 DBMET00960 | DBMET03516 | |
| 0 | 0.968 | 0.019 | Alpha 2b adrenoreceptor agonist | 0.019 0.012 DBMET03516 | DBMET03516 | |
| 0.001 | 0.969 | 0.047 | Glutamate (mGluR3) antagonist | 0.047 0.015 DBMET03516 | DBMET03516 | |
| 0 | 0.969 | 0.137 | Alpha 1b adrenoreceptor antagonist | 0.137 0.025 DBMET03516 0.136 0.025 DBMET00960 | DBMET03516 | |
| 0.003 | 0.971 | 0.128 | mTOR complex 2 inhibitor | 0.128 0.014 DBMET03516 0.082 0.064 DBMET00960 | DBMET03516 | |
| 0.003 | 0.971 | 0.3 | Hypoxia-inducible factor 1 alpha inhibitor | 0.3 0.066 DBMET03516 | DBMET03516 | |
| 0.001 | 0.969 | 0.077 | Sphingosine 1-phosphate receptor 4 agonist | 0.077 0.039 DBMET03516 | DBMET03516 | |
| 0.001 | 0.969 | 0.079 | Fibroblast growth factor 2 antagonist | 0.079 0.035 DBMET03516 | DBMET03516 | |
| 0 | 0.969 | 0.075 | Kainate receptor 2 antagonist | 0.075 0.008 DBMET03516 | DBMET03516 | |
| 0.002 | 0.971 | 0.21 | Nav1.6 sodium channel blocker | 0.21 0.016 DBMET03516 | DBMET03516 | |
| 0.002 | 0.971 | 0.054 | Glutamate (mGluR4) antagonist | 0.054 0.018 DBMET03516 | DBMET03516 | |
| 0.001 | 0.97 | 0.157 | Polo-like kinase-1 inhibitor | 0.153 0.015 DBMET03516 0.157 0.014 DBMET00960 | DBMET00960 | |
| 0.003 | 0.973 | 0.084 | Exportin-1 inhibitor | 0.084 0.021 DBMET03516 0.069 0.045 DBMET00960 | DBMET03516 | |
| 0.003 | 0.972 | 0.086 | Protein kinase C alpha inhibitor | 0.086 0.029 DBMET03516 | DBMET03516 | |
| 0.001 | 0.97 | 0.059 | mTOR inhibitor | 0.059 0.029 DBMET03516 | DBMET03516 | |
| 0.002 | 0.971 | 0.135 | Heat shock protein 90 alpha antagonist | 0.135 0.104 DBMET03516 | DBMET03516 | |
| 0.001 | 0.97 | 0.047 | Lysophosphatidic acid 3 receptor antagonist | 0.047 0.041 DBMET03516 | DBMET03516 | |
| 0 | 0.97 | 0.17 | 5 Hydroxytryptamine 1B antagonist | 0.17 0.011 DBMET03516 | DBMET03516 | |
| 0.005 | 0.975 | 0.108 | Estrogen-related receptor beta agonist | 0.108 0.016 DBMET03516 0.086 0.049 DBMET00960 | DBMET03516 | |
| 0.004 | 0.974 | 0.367 | Vasodilator, coronary | 0.367 0.048 DBMET03516 0.241 0.143 DBMET00960 | DBMET03516 | |
| 0.003 | 0.973 | 0.165 | DNA repair enzyme inhibitor | 0.165 0.02 DBMET03516 0.125 0.063 DBMET00960 | DBMET03516 | |
| 0.001 | 0.971 | 0.102 | Delayed rectifier potassium channel blocker | 0.102 0.004 DBMET03516 | DBMET03516 | |
| 0.002 | 0.972 | 0.132 | Protein kinase C beta inhibitor | 0.132 0.005 DBMET03516 | DBMET03516 | |
| 0.001 | 0.971 | 0.073 | Glycine transporter 2 inhibitor | 0.073 0.02 DBMET03516 | DBMET03516 | |
| 0.001 | 0.972 | 0.101 | Potassium channel (Tandem pore domain) blocker | 0.101 0.009 DBMET03516 0.069 0.066 DBMET00960 | DBMET03516 | |
| 0.003 | 0.974 | 0.144 | MAP kinase 3 inhibitor | 0.144 0.078 DBMET03516 | DBMET03516 | |
| 0.002 | 0.973 | 0.029 | Dopamine D1 agonist | 0.029 0.009 DBMET03516 | DBMET03516 | |
| 0.004 | 0.975 | 0.131 | Anabolic | 0.131 0.03 DBMET03516 0.109 0.051 DBMET00960 | DBMET03516 | |
| 0 | 0.971 | 0.046 | Acid ceramidase inhibitor | 0.046 0.004 DBMET03516 0.025 0.02 DBMET00960 | DBMET03516 | |
| 0 | 0.972 | 0.103 | Alpha 1a adrenoreceptor antagonist | 0.103 0.035 DBMET03516 | DBMET03516 | |
| 0.001 | 0.972 | 0.198 | Creatine kinase inhibitor | 0.198 0.011 DBMET03516 0.152 0.023 DBMET00960 | DBMET03516 | |
| 0.001 | 0.972 | 0.179 | 5 Hydroxytryptamine 2C antagonist | 0.179 0.02 DBMET03516 | DBMET03516 | |
| 0.003 | 0.975 | 0.197 | ATPase inhibitor | 0.197 0.039 DBMET03516 | DBMET03516 | |
| 0 | 0.972 | 0.047 | AMPA receptor antagonist | 0.047 0.034 DBMET03516 | DBMET03516 | |
| 0.003 | 0.975 | 0.114 | TRPA1 agonist | 0.114 0.065 DBMET03516 | DBMET03516 | |
| 0.001 | 0.973 | 0.077 | Amidase inhibitor | 0.077 0.04 DBMET03516 | DBMET03516 | |
| 0.001 | 0.973 | 0.028 | Integrin alpha2beta1 antagonist | 0.028 0.016 DBMET03516 | DBMET03516 | |
| 0 | 0.973 | 0.048 | Estrogen-related receptor gamma antagonist | 0.048 0.004 DBMET03516 0.031 0.014 DBMET00960 | DBMET03516 | |
| 0 | 0.973 | 0.04 | Phosphoglycerate kinase inhibitor | 0.04 0.02 DBMET03516 | DBMET03516 | |
| 0.002 | 0.975 | 0.267 | Kinesin-like protein 1 inhibitor | 0.267 0.004 DBMET00960 | DBMET00960 | |
| 0.002 | 0.975 | 0.267 | Kinesin antagonist | 0.267 0.004 DBMET00960 | DBMET00960 | |
| 0.002 | 0.975 | 0.12 | Sphingosine 1-phosphate receptor 4 antagonist | 0.12 0.071 DBMET03516 | DBMET03516 | |
| 0.004 | 0.977 | 0.235 | Neuropeptide Y2 antagonist | 0.235 0.071 DBMET03516 | DBMET03516 | |
| 0.002 | 0.975 | 0.09 | Interferon inducer | 0.09 0.017 DBMET03516 | DBMET03516 | |
| 0.003 | 0.977 | 0.196 | Histone acetyltransferase inhibitor | 0.196 0.075 DBMET03516 | DBMET03516 | |
| 0 | 0.974 | 0.045 | Kainate receptor antagonist | 0.045 0.025 DBMET03516 | DBMET03516 | |
| 0.001 | 0.974 | 0.072 | Squalene epoxidase inhibitor | 0.072 0.013 DBMET03516 | DBMET03516 | |
| 0.002 | 0.976 | 0.144 | Heat shock protein 90 antagonist | 0.144 0.081 DBMET03516 | DBMET03516 | |
| 0.003 | 0.977 | 0.18 | Sphingomyelinase inhibitor | 0.18 0.014 DBMET03516 0.087 0.076 DBMET00960 | DBMET03516 | |
| 0 | 0.974 | 0.091 | Glycine transporter inhibitor | 0.091 0.013 DBMET03516 | DBMET03516 | |
| 0.001 | 0.975 | 0.176 | Alpha adrenoreceptor antagonist | 0.165 0.034 DBMET03516 0.176 0.031 DBMET00960 | DBMET00960 | |
| 0.004 | 0.978 | 0.139 | Hexokinase inhibitor | 0.139 0.093 DBMET03516 | DBMET03516 | |
| 0.001 | 0.975 | 0.176 | Sphingosine 1-phosphate receptor 2 antagonist | 0.176 0.017 DBMET03516 0.125 0.084 DBMET00960 | DBMET03516 | |
| 0 | 0.975 | 0.05 | 5 Hydroxytryptamine 2B agonist | 0.05 0.013 DBMET03516 | DBMET03516 | |
| 0.001 | 0.975 | 0.023 | ICAM 1 antagonist | 0.023 0.016 DBMET03516 | DBMET03516 | |
| 0.003 | 0.977 | 0.158 | Triose-phosphate isomerase inhibitor | 0.158 0.018 DBMET03516 0.143 0.022 DBMET00960 | DBMET03516 | |
| 0 | 0.975 | 0.009 | Integrin alpha5beta6 antagonist | 0.009 0.003 DBMET03516 | DBMET03516 | |
| 0.001 | 0.976 | 0.097 | 5 Hydroxytryptamine 2A agonist | 0.097 0.015 DBMET03516 | DBMET03516 | |
| 0.001 | 0.976 | 0.037 | Integrin alpha2 antagonist | 0.037 0.024 DBMET03516 | DBMET03516 | |
| 0 | 0.975 | 0.016 | Thromboxane A2 agonist | 0.016 0.01 DBMET03516 | DBMET03516 | |
| 0.001 | 0.976 | 0.171 | Alpha 1 adrenoreceptor antagonist | 0.123 0.036 DBMET03516 0.171 0.025 DBMET00960 | DBMET00960 | |
| 0.001 | 0.977 | 0.229 | Phosphodiesterase IV inhibitor | 0.229 0.009 DBMET00960 | DBMET00960 | |
| 0.001 | 0.977 | 0.027 | Geranylgeranyltransferase inhibitor | 0.027 0.011 DBMET03516 | DBMET03516 | |
| 0.001 | 0.977 | 0.086 | Potassium channel (Inward rectifier) blocker | 0.086 0.01 DBMET03516 | DBMET03516 | |
| 0.001 | 0.978 | 0.429 | Psychostimulant | 0.429 0.018 DBMET03516 0.197 0.081 DBMET00960 | DBMET03516 | |
| 0.002 | 0.979 | 0.118 | Aldehyde dehydrogenase inhibitor | 0.118 0.073 DBMET03516 | DBMET03516 | |
| 0.001 | 0.978 | 0.115 | Phospholipase D inhibitor | 0.115 0.008 DBMET03516 0.072 0.049 DBMET00960 | DBMET03516 | |
| 0.001 | 0.979 | 0.031 | Hedgehog signaling activator | 0.031 0.011 DBMET03516 | DBMET03516 | |
| 0.003 | 0.981 | 0.499 | Vasodilator, peripheral | 0.499 0.028 DBMET03516 0.242 0.133 DBMET00960 | DBMET03516 | |
| 0.003 | 0.98 | 0.135 | Melanin inhibitor | 0.135 0.105 DBMET03516 | DBMET03516 | |
| 0.001 | 0.978 | 0.075 | Pregnane X receptor antagonist | 0.075 0.009 DBMET03516 0.055 0.045 DBMET00960 | DBMET03516 | |
| 0.001 | 0.978 | 0.054 | Heme oxygenase inhibitor | 0.054 0.009 DBMET03516 0.043 0.029 DBMET00960 | DBMET03516 | |
| 0.001 | 0.978 | 0.08 | Myeloperoxidase inhibitor | 0.08 0.066 DBMET03516 | DBMET03516 | |
| 0.001 | 0.979 | 0.055 | Glucosylceramidase inhibitor | 0.055 0.038 DBMET03516 | DBMET03516 | |
| 0 | 0.978 | 0.089 | 5 Hydroxytryptamine 2 agonist | 0.089 0.012 DBMET03516 | DBMET03516 | |
| 0.003 | 0.981 | 0.372 | Phosphodiesterase inhibitor | 0.372 0.009 DBMET00960 | DBMET00960 | |
| 0 | 0.978 | 0.044 | NMDA 2A receptor antagonist | 0.044 0.043 DBMET03516 | DBMET03516 | |
| 0.001 | 0.979 | 0.053 | GABA B receptor antagonist | 0.053 0.017 DBMET03516 | DBMET03516 | |
| 0.012 | 0.99 | 0.716 | 5 Hydroxytryptamine release stimulant | 0.716 0.006 DBMET03516 0.425 0.041 DBMET00960 | DBMET03516 | |
| 0 | 0.979 | 0.019 | 5-Alpha-reductase 2 inhibitor | 0.019 0.014 DBMET03516 | DBMET03516 | |
| 0 | 0.979 | 0.081 | NMDA 2C receptor antagonist | 0.081 0.024 DBMET03516 | DBMET03516 | |
| 0 | 0.979 | 0.017 | 5-Alpha-reductase 1 inhibitor | 0.017 0.012 DBMET03516 | DBMET03516 | |
| 0.001 | 0.979 | 0.096 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.096 0.039 DBMET03516 0.076 0.054 DBMET00960 | DBMET03516 | |
| 0 | 0.98 | 0.015 | Integrin beta2 antagonist | 0.015 0.007 DBMET03516 | DBMET03516 | |
| 0.001 | 0.98 | 0.196 | Protein kinase C gamma inhibitor | 0.196 0.015 DBMET03516 | DBMET03516 | |
| 0.003 | 0.982 | 0.128 | Vanilloid 1 agonist | 0.128 0.069 DBMET03516 | DBMET03516 | |
| 0.003 | 0.983 | 0.136 | HIV-1 integrase (Overall Integration) inhibitor | 0.136 0.031 DBMET03516 | DBMET03516 | |
| 0.004 | 0.984 | 0.125 | Lanosterol 14 alpha demethylase inhibitor | 0.125 0.026 DBMET03516 | DBMET03516 | |
| 0.001 | 0.981 | 0.083 | I kappa B kinase inhibitor | 0.083 0.057 DBMET03516 | DBMET03516 | |
| 0.001 | 0.981 | 0.075 | Epoxide hydrolase inhibitor | 0.075 0.047 DBMET03516 | DBMET03516 | |
| 0.001 | 0.981 | 0.028 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.028 0.014 DBMET03516 | DBMET03516 | |
| 0.003 | 0.983 | 0.345 | Superoxide dismutase inhibitor | 0.345 0.037 DBMET03516 0.243 0.079 DBMET00960 | DBMET03516 | |
| 0.001 | 0.982 | 0.068 | I kappa B kinase 2 inhibitor | 0.068 0.035 DBMET03516 | DBMET03516 | |
| 0.003 | 0.984 | 0.221 | Protein kinase stimulant | 0.221 0.035 DBMET03516 | DBMET03516 | |
| 0.002 | 0.984 | 0.177 | NADPH oxidase inhibitor | 0.177 0.042 DBMET03516 | DBMET03516 | |
| 0.002 | 0.983 | 0.648 | Aldehyde oxidase inhibitor | 0.648 0.013 DBMET03516 0.261 0.078 DBMET00960 | DBMET03516 | |
| 0.001 | 0.983 | 0.189 | Arachidonic acid antagonist | 0.189 0.044 DBMET03516 0.166 0.07 DBMET00960 | DBMET03516 | |
| 0.003 | 0.985 | 0.259 | Phosphodiesterase III inhibitor | 0.259 0.005 DBMET00960 | DBMET00960 | |
| 0.007 | 0.989 | 0.445 | Histamine release inhibitor | 0.445 0.052 DBMET03516 0.207 0.193 DBMET00960 | DBMET03516 | |
| 0.006 | 0.988 | 0.132 | Interleukin 2 antagonist | 0.132 0.031 DBMET03516 | DBMET03516 | |
| 0 | 0.983 | 0.037 | LFA antagonist | 0.037 0.009 DBMET03516 | DBMET03516 | |
| 0.001 | 0.983 | 0.046 | Thymidine kinase inhibitor | 0.046 0.022 DBMET03516 | DBMET03516 | |
| 0.002 | 0.984 | 0.347 | Cyclic AMP phosphodiesterase inhibitor | 0.347 0.026 DBMET03516 | DBMET03516 | |
| 0 | 0.983 | 0.046 | Purinergic P2Y antagonist | 0.046 0.03 DBMET03516 | DBMET03516 | |
| 0.001 | 0.984 | 0.054 | Aldosterone antagonist | 0.054 0.024 DBMET03516 | DBMET03516 | |
| 0.004 | 0.987 | 0.649 | Antiobesity | 0.255 0.152 DBMET03516 0.649 0.015 DBMET00960 | DBMET00960 | |
| 0.001 | 0.983 | 0.096 | Adenylate cyclase 1 inhibitor | 0.096 0.005 DBMET03516 0.042 0.038 DBMET00960 | DBMET03516 | |
| 0.003 | 0.986 | 0.117 | Cyclooxygenase 3 inhibitor | 0.117 0.081 DBMET03516 | DBMET03516 | |
| 0.002 | 0.986 | 0.183 | Nav1.2 sodium channel blocker | 0.183 0.041 DBMET03516 | DBMET03516 | |
| 0.005 | 0.988 | 0.133 | Photosensitizer | 0.133 0.044 DBMET03516 | DBMET03516 | |
| 0.002 | 0.986 | 0.179 | Adenylate cyclase inhibitor | 0.179 0.03 DBMET03516 | DBMET03516 | |
| 0.001 | 0.985 | 0.083 | MDM2 inhibitor | 0.083 0.016 DBMET03516 | DBMET03516 | |
| 0.004 | 0.988 | 0.16 | Antimitotic | 0.16 0.112 DBMET00960 | DBMET00960 | |
| 0.004 | 0.989 | 0.673 | Tumour necrosis factor alpha release inhibitor | 0.673 0.005 DBMET00960 | DBMET00960 | |
| 0.001 | 0.986 | 0.163 | Beta amyloid protein antagonist | 0.163 0.032 DBMET03516 | DBMET03516 | |
| 0.003 | 0.988 | 0.187 | Protein kinase C delta inhibitor | 0.111 0.043 DBMET03516 0.187 0.01 DBMET00960 | DBMET00960 | |
| 0.001 | 0.985 | 0.074 | NMDA receptor antagonist | 0.074 0.073 DBMET03516 | DBMET03516 | |
| 0 | 0.985 | 0.023 | Thymidine kinase (Herpes simplex virus 2) inhibitor | 0.023 0.01 DBMET03516 | DBMET03516 | |
| 0 | 0.985 | 0.039 | 5-Alpha-reductase inhibitor | 0.039 0.025 DBMET03516 | DBMET03516 | |
| 0.002 | 0.987 | 0.155 | Non-steroidal antiinflammatory agent | 0.155 0.109 DBMET03516 | DBMET03516 | |
| 0.001 | 0.986 | 0.186 | Pregnane X receptor agonist | 0.186 0.015 DBMET03516 0.128 0.106 DBMET00960 | DBMET03516 | |
| 0.001 | 0.987 | 0.264 | Toll-Like receptor antagonist | 0.264 0.012 DBMET03516 | DBMET03516 | |
| 0.001 | 0.986 | 0.08 | Estrogen receptor alpha antagonist | 0.08 0.049 DBMET03516 | DBMET03516 | |
| 0.001 | 0.986 | 0.082 | Fatty acid synthase inhibitor | 0.082 0.018 DBMET03516 | DBMET03516 | |
| 0.001 | 0.987 | 0.156 | Toll-Like receptor 2 antagonist | 0.156 0.048 DBMET03516 | DBMET03516 | |
| 0.001 | 0.987 | 0.097 | Phosphodiesterase VI inhibitor | 0.097 0.022 DBMET03516 | DBMET03516 | |
| 0.001 | 0.987 | 0.08 | Androgen antagonist | 0.08 0.066 DBMET03516 | DBMET03516 | |
| 0.004 | 0.99 | 0.17 | P-glycoprotein inhibitor | 0.17 0.09 DBMET03516 | DBMET03516 | |
| 0.001 | 0.988 | 0.14 | Cathepsin H inhibitor | 0.14 0.054 DBMET03516 0.115 0.082 DBMET00960 | DBMET03516 | |
| 0.002 | 0.989 | 0.106 | Bile acid receptor antagonist | 0.106 0.038 DBMET03516 | DBMET03516 | |
| 0.002 | 0.988 | 0.142 | Phosphodiesterase 6D inhibitor | 0.142 0.012 DBMET03516 | DBMET03516 | |
| 0 | 0.987 | 0.065 | 2,3-Oxidosqualene-lanosterol cyclase inhibitor | 0.065 0.006 DBMET03516 0.062 0.007 DBMET00960 | DBMET03516 | |
| 0.002 | 0.99 | 0.195 | Antiamyloidogenic | 0.195 0.103 DBMET03516 | DBMET03516 | |
| 0.002 | 0.989 | 0.179 | Adenylate cyclase stimulant | 0.179 0.027 DBMET03516 0.151 0.061 DBMET00960 | DBMET03516 | |
| 0.005 | 0.993 | 0.079 | T cell inhibitor | 0.079 0.068 DBMET03516 | DBMET03516 | |
| 0.001 | 0.99 | 0.25 | Neurotrophic factor enhancer | 0.25 0.039 DBMET03516 | DBMET03516 | |
| 0.002 | 0.991 | 0.167 | Interleukin 8 antagonist | 0.167 0.024 DBMET03516 | DBMET03516 | |
| 0.001 | 0.99 | 0.123 | Cholesterol synthesis inhibitor | 0.123 0.063 DBMET03516 | DBMET03516 | |
| 0 | 0.99 | 0.088 | Androgen agonist | 0.088 0.02 DBMET03516 | DBMET03516 | |
| 0.002 | 0.991 | 0.135 | Mineralocorticoid receptor antagonist | 0.135 0.005 DBMET00960 | DBMET00960 | |
| 0.001 | 0.992 | 0.12 | Cytokine production inhibitor | 0.12 0.089 DBMET03516 | DBMET03516 | |
| 0.003 | 0.994 | 0.161 | Interferon gamma antagonist | 0.161 0.065 DBMET03516 0.125 0.123 DBMET00960 | DBMET03516 | |
| 0.002 | 0.992 | 0.274 | Transcription factor STAT inhibitor | 0.274 0.071 DBMET03516 | DBMET03516 | |
| 0.002 | 0.993 | 0.174 | Hemostatic | 0.174 0.046 DBMET03516 0.161 0.056 DBMET00960 | DBMET03516 | |
| 0.001 | 0.994 | 0.241 | Transcription factor STAT3 inhibitor | 0.241 0.09 DBMET03516 | DBMET03516 | |
| 0.002 | 0.995 | 0.218 | Transcription factor NF kappa B inhibitor | 0.218 0.153 DBMET03516 | DBMET03516 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |